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Abstract
Liver fibrosis, that is, excessive accumulation of extracellular matrix protein, occurs and is
the wound-healing response and common final pathway of various chronic liver diseases.
Advanced hepatic fibrosis caused by chronic liver inflammation eventually progresses to
cirrhosis, and prognosis and management of chronic liver diseases depend on the fibrotic
severities. Therefore, the early and precise evaluation of severity and status of liver fibrosis
provides useful information for diagnosis as well as treatment planning and treatment
efficacy and prognosis. Although invasive liver biopsy is the gold standard to assess the
nature and severity of hepatic fibrosis, it has several recognized limitations including sam-
pling error and inter-observer variability in interpretation and staging. Furthermore, the
dynamic process of fibrosis resulting from progression and regression is difficult to capture
with biopsy alone. Therefore, alternative, simple, reliable, and noninvasive direct and indi-
rect serummarkers able to predict the presence of significant fibrosis or cirrhosis in patients
with chronic liver disease with considerable accuracy were needed. The hepatology experts
are actively researching noninvasive methods of fibrosis quantification. The aims of this
chapterwere to review the nature and limitations of the several noninvasivemethods for the
assessment of presence and severity of liver fibrosis in patients with chronic liver disease.
Keywords: noninvasive method, biomarker, stage of liver fibrosis, cirrhosis, chronic
liver disease
1. Introduction
Liver fibrosis and cirrhosis are an important and growing global health problem. Patients with
non-cirrhotic chronic liver disease may have an increased mortality rate compared to con-
trols [1]. However, mortality and morbidity rates increase exponentially once cirrhosis
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develops. Prognosis and management of chronic liver diseases greatly depend on the amount
and progression of liver fibrosis. Therefore, the ability to reliably rule out cirrhosis may be
considered an important characteristic of any test designed to assess liver fibrosis [2]. The
diagnosis of cirrhosis also portends an increased risk of liver-related morbidity [3] as well as
mortality [4]. Liver-related mortality and decompensation are expected to continue to increase
over the next decade, due to the projected increase in the number of patients with advanced
liver fibrosis in the population [5]. Therefore, the accurate and timely evaluation of liver
fibrosis is a key step to manage a chronic liver disease and to assess its prognosis and in need
of close monitoring, management of complications, and underlying liver disease in patients
with advanced stages [6]. For many years, liver biopsy has been considered the “gold stan-
dard” for evaluation of liver fibrosis [7]. Pathologists have proposed robust scoring system for
staging liver fibrosis such as the semi-quantitative Metavir score (F0: no fibrosis, F1: portal
fibrosis, F2: bridging fibrosis, F3; bridging fibrosis, and marked, F4: cirrhosis) [8] and the
modified Ishak score, an expansion of Metavir score [9]. In addition, computer-aided morpho-
metric measurement of collagen-proportional area, a partly automated technique, provides an
accurate and linear evaluation of the amount of fibrosis [10]. However, liver biopsy is an
invasive procedure with rare but potentially life-threatening complications and prone to sam-
pling errors. Also, liver biopsy gives a snapshot and not an insight into the dynamic changes
during the process of fibrogenesis (progression, atatic, or regression). Therefore, liver biopsy
has some limitations as follows. First, biopsy is an invasive technique, which has associated
morbidity; pain occurs in 20% of patients and major complications such as bleeding or
hemobilia in 0.5% [11]. The bleeding rate (0.5%) has not changed significantly in recent years,
according to a large multicenter study [12]. The primary factor that appeared to contribute to
bleeding risk was platelet count rather than qualitative factors such as operator experience,
needle size, or the use of ultrasound to localize the site. Second, the small size of the biopsy
makes it prone to sampling variability [13]. Third, the interpretation of the histologic changes
can be problematic with inter- and intra-observer variation [14]. These limitations as well as
the availability of powerful viral diagnostic tools and new antiviral drugs have rapidly
decreased the use of liver biopsy in viral hepatitis and led to the development of noninvasive
techniques for the assessment of liver fibrosis. On the other hand, at least some correlation
between biopsy stage and outcomes has begun to emerge. In the NIH-HALT C cohort, a
correlation was found between the Ishak fibrosis stage and clinical outcomes, the need of liver
transplantation, and liver-related deaths in patients with chronic HCV. However, even in this
study, up to 25% of the liver biopsy samples were fragmented, which significantly diminished
the ability to draw correlations between biopsy findings and clinical outcomes [15]. While
some of these methodologies are now generally applied in patients for a top priority of
evaluation, biopsy exists within the clinical technique of hepatologists for estimating the
causes of complicated diseases or when there are unconformities between clinical characteris-
tics and extents of fibrosis evaluated by noninvasive methodologies [16]. The dynamic process
of fibrosis should be best measured as a continuous variable and classical histological staging
systems do not permit this [17]. Since liver biopsy is an invasive procedure, cost-intensive,
mostly uncomfortable for the patients, and sometimes prone to complication, alternative,
simple noninvasive tests have been developed to reliably assess the stage of liver fibrosis.
Ongoing efforts include serum markers and imaging based on ultrasound, computed
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tomography (CT), and magnetic resonance imaging (MRI). The goal is to develop tests with
high specificity and sensitivity to estimate liver fibrosis and predict outcomes [18]. Ideally,
noninvasive methodologies of liver fibrosis should be liver specific, easy to perform, reliable,
and inexpensive. In addition, it should be accurate not only for the staging of fibrosis but also
for the monitoring of disease progression and antiviral therapy efficacy [19]. Scientific atten-
tion is currently focused on new antifibrotic therapies, aiming at fibrosis reversibility and
cirrhosis regression [20]. It is therefore important, now more than ever, to ensure accurate and
prompt assessment of hepatic fibrosis in therapeutic trials of chronic liver disease. Conse-
quently, the demand for noninvasive method substitutes to estimate hepatic fibrosis is a main
trial that has provoked research and induced the improvement of noninvasive serological
markers of hepatic fibrosis. Several noninvasive serological markers have been described to
forecast the existence of significant fibrosis or cirrhosis in patients with chronic hepatic disease
with good accuracy. However, most of these markers require complicated calculations, and
manipulation in various clinical situations is difficult and inconvenient [21]. Recently, transient
elastography (TE, FibroScan) has been introduced as a novel, rapid, noninvasive, and repro-
ducible method to measure liver stiffness [22]. In several studies [22, 23], liver stiffness mea-
surement (LSM) using M probe of FibroScan accurately predicted hepatic fibrosis and cirrhosis
in patients with chronic liver disease.
This chapter focuses and provides comparison of invasive and noninvasive methods for
assessing the severity of liver fibrosis and aims to provide update on noninvasive diagnostic
and prognostic assessment tools for liver fibrosis and cirrhosis in patients with chronic liver
disease.
2. Mechanism of liver fibrosis
Liver fibrosis is the result of the continuous wound-healing process of the liver to repeated
damage [24]. After acute liver injury (e.g., viral hepatitis), parenchymal cells regenerate and
replace the necrotic or apoptotic cells. The process is associated with a hepatic inflammatory
response and a limited deposition of extracellular matrix (ECM) in the hepatic parenchyma. If
the liver injury persists, then eventually the liver regeneration fails, and hepatocytes are
substituted with abundant ECM, including fibrillar collagen [25]. This process results in cir-
rhosis, which can have a bad outcome and high mortality. Progression to this end stage is
typically variable but slow, developing over 20–40 years in patients with chronic liver damage;
the speed is dependent on both genetic and environmental factors [26]. Liver fibrosis is a
common pathological consequence of a variety of chronic stimuli, including viral, alcohol,
and autoimmune, drug-induced, cholestatic and metabolic diseases [18, 26–28]. Deposition of
excess ECM is rich in fibril-forming collagens [29], which change the normal structure of the
liver resulting in pathophysiologic damage to the organ [30]. Liver fibrosis is beneficial at first
because it can encapsulate the injury and is considered a reversible process at this stage [31]. In
normal liver, ECM is highly dynamic substratum with a precisely regulated balance between
synthesis and degradation. Normally, the hepatic ECM comprises less than 3% of the relative
area on a liver tissue section and approximately 0.5% of the total wet weight of liver [32]. It is
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also a component of Glisson’s capsule, portal tracts, central veins, and the subendothelial space
of Disse. The most important structural ECM components in liver are collagen, proteoglycans,
laminin, fibronectin, and matricellular proteins. The hepatic parenchyma is composed of
hepatocytes, endothelial cells, and other resident cells, including hepatic stellate cell (HSCs)
and Kupffer cells (KCs). The sinusoid is the hepatic microvascular unit that has an endothelial
lining distinguished by fenestration of pores and is separated from the hepatocytes by the
space of Disse, where HSCs reside. This space contains a low-density basal membrane-like
matrix that is essential for maintaining the differentiated function of parenchymal cell yet is
sufficiently porous to enable metabolic exchange between the bloodstream and hepato-
cytes [26]. During chronic liver injury, however, ECM production exceeds ECM degradation,
and liver fibrosis develops as results of the progressive thickening of fibrotic septae and
chemical cross-linking of collagen. Moreover, these changes in ECM composition directly
stimulate fibrogenesis (Figure 1) [33]. After liver injury, disruption of this matrix and replace-
ment by fibrillar collagens I and III and fibronectin have occurred [34, 35]. Fibrosis is charac-
terized histologically and biochemically by a several-fold elevation in the total ECM content of
the liver [25].
Accumulation of ECM in the space of Disse leads to loss of the normal fenestrating structures
that are characteristic of the endothelial lining, which causes the impairment of the normal
bidirectional metabolic exchange between portal blood and hepatocytes. This process is sinu-
soidal remodeling, termed capillarization of the sinusoid [38]. All major constituents of normal
ECM are represented, to some extent, in the newly formed matrix during the fibrogenic
process. As in normal ECM, collagen (especially types I and III) and elastin are most abundant
proteins, but glycoproteins (fibronectin and laminin) and pure carbohydrates are also present.
When compared to normal matrix, scar tissue produced in liver fibrosis has a significantly
higher percentage of type I collagen [39]. ECM deposition occurs as a result of an imbalance
between excessive ECM production and less degradation. In the normal liver, matrix
metalloproteinases (MMPs) have a well-described ECM-degrading function. The activity of
MMPs, however, is suppressed in the setting of liver injury as a result of overexpression of
tissue inhibitor of metalloproteinase (TIMPs) by the activated HSCs [25]. TIMPs are key
regulators of MMPs, by blocking their collagenolytic activity. In addition, TIMP-1 is anti-
apoptotic toward HSCs, in part through the induction of Bcl-2, thus promoting the survival of
fibrogenic cells [40]. This balance between MMPs and TIMPs is crucial for ECM homeosta-
sis [41]. In human liver, the degree of TIPM-1 expression correlates with the extent of liver
fibrosis [42]. In order to preserve matrix homeostasis, ECM also contains MMPs, MMP-1,
MMP-8, and MMP-13 that degrade the fibrillary collagen types I and III predominating in
fibrosis, while MMP-2 and MMP-9 degrade collagen types IV as well as denatured fibrillary
collagens. HSCs are the key source of both MMPs in liver. Although the increase of MMP
production should control the excessive increase of the ECM, it can also promote injury. Early
increases in MMP, particularly MMP-2, degrade normal matrix and recruit cells that amplify
fibrosis [43, 44]. In addition, there is also enhanced secretion of TIMP-1 and -2 by HSCs during
progressive tissue injury and cellular activation. Different populations of cells play roles in
fibrogenesis, but the activation of HSCs is an essential factor in fibrinogenesis [45]. The mech-
anism of liver fibrosis is thought to be associated with the hepatic damage of various etiologic
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factors followed by the activation of HSCs within the liver that develop into liver myofibro-
blasts (LMFs) [46]. LMFs include a heterogeneous population of highly proliferative cells that
accumulate at injury sites and promote ECM accumulation [47]. The pool of LMF originates
mainly from liver mesenchymal cells, namely HSCs [48]. Although HSCs are the primary
source of LMFs in liver fibrosis, extrahepatic precursors such as bone marrow-derived mesen-
chymal cells and portal fibroblasts contribute in ECM production [49, 50]. HSCs are resident
peri-sinusoidal cells in the subendothelial space of Disse between hepatocytes and sinusoidal
endothelial cells. The main cells affected by liver fibrosis are the HSCs and fibroblasts, which
are activated by soluble mediators produced by activated KCs or inflammatory cells in the
course of chronic liver disease [51]. ECMmay thereby regulate cellular activity and availability
of growth factors. For instance, decorin and biglycan, two ECM components, bind
transforming growth factor-β (TGF-β), fibronectin and laminin bind tumor necrosis factor-α
(TNF-α), and collagen binds platelet-derived growth factor (PDGF), hepatocyte growth factor
(HGF), and interleukin-2 (IL-2). The binding of survival factors to the ECM may prevent
apoptosis of hepatocyte in the pathologic condition and also prevent growth factor degrada-
tion [33]. In liver tissues, HSCs store retinoids such as vitamin A and produce glial fibrillary
acidic protein (GFAP), the so-called fat-storing cells or vitamin A-rich cells [52]. Following liver
injury, HSCs become activated, which leads to the conversion of a quiescent to activated HSCs
that has lost vitamin A droplets, leading to increased proliferation and contraction and the
release of proinflammatory, profibrogenic, and promitogenic cytokines. These activated HSCs
are capable of enhanced migration and deposition of ECM components [46, 53]. The activation
of HSCs can be divided into two stages: initiation and perpetuation [46]. In the first or initiation
Figure 1. Schematic illustration of fibrosis progression and regression (modified from Refs. [18, 36, 37]).
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phase, HSCs undergo the initial changes toward a myofibroblast-like cell differentiation and
become more responsive to proliferative and fibrogenic cytokines by up-regulation of mem-
brane receptors [54]. This stage also called a “pre-inflammatory” stage refers to early changes
in gene expression that result primarily from paracrine stimuli derived from damaged resident
liver cells (sinusoidal endothelial cells, KCs, and hepatocytes) and platelets. KCs engagement
drives release cytokines (especially TGF-β) and ROS signaling [55]. Endothelial cells partici-
pate in the conversion of latent TGF-β into active form and produce fibronectin, which also
provokes early HSC activation. In addition, PDGF, TGF-β, and endothelial growth factor
(EGF) which is potent activators of HSCs [56]. Persistence of these stimuli accompanying
sustained injury leads to a perpetuation stage regulated by autocrine and paracrine stimuli.
Perpetuation stage involves at least seven distinct changes in HSC behavior, including prolif-
eration, chemotaxis, fibrogenesis, contractility, altered matrix degradation, retinoid loss, and
inflammatory signaling [57]. Therefore, a critical event in liver fibrogenesis is that the ECM is a
dynamic structure, and even advanced fibrosis may be reversible [58, 59]. Multiple interactions
between the ECM, HSCs, endothelial cells, and immune cells have been identified. The central
event in liver fibrogenesis appears to be the activation of HSCs, which is a complex pro-
cess [59]. Different patterns of fibrosis progression have been described on the basis of their
etiology, region of injury (e.g., portal or central), the source of fibrogenic cells involved, and the
predominant fibrogenic mechanisms [60]. For example, chronic viral hepatitis B and C are
major causes of bridging fibrosis, resulting in the formation of portal-central fibrotic septa.
Perisinusoidal or pericellular fibrosis is typically found in alcohol-related disorders and
nonalcoholic fatty liver disease (NAFLD). Progression of hepatic pathology with sustained
fibrogenesis leads to cirrhosis, which is not merely the end-stage accumulation of scar, but
rather is characterized by a destruction of the hepatic parenchyma and vascular architecture.
The main pathological characteristic of cirrhosis is the formation of nodules of regenerative
parenchyma enclosed by fibrotic septa, which may contain terminal hepatic venules and portal
tracts when the nodules are especially large (i.e., macronodular cirrhosis). Portosystemic
shunts and venous occlusion often occur, leading to impairment in liver function and the
development of portal hypertension. The formation of vascularized fibrous septa that link
portal tracts and central veins is stimulated by angiogenesis and contributes to portosystemic
shunting that bypasses the liver parenchyma [61].
3. Liver biopsy: pros and cons, and limitations
Liver biopsy is usually known as the most specific test to evaluate the feature and severity of
liver pathology and can be useful in monitoring the efficacy of various treatments. There are
currently several techniques available for obtaining liver tissue and each of these has pros and
cons [7]. The size of the biopsy specimen, which varies between 10 and 30 mm in length and
between 1.2 and 2 mm in diameter, represents only 1:50,000 of the total mass of liver [62].
Therefore, in disease affecting the liver in a diverse way, the histologic findings of biopsy
specimen may not be representative of the pathologic process. However, most cases of chronic
liver disease causing fibrosis, such as viral and autoimmune hepatitis, as well as nonalcoholic
steatohepatitis (NASH), affect the liver in a relatively uniform pattern [63]. Then the extent, to
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which the biopsy will be representative, will depend greatly on the size of the specimen
obtained. The number of portal triads present in the specimen is important; most
hepatopathologists are satisfied with a biopsy specimen containing at least 6–8 portal triads.
The indications of liver biopsy are outlined in Table 1 [7].
Even for patients where serological tests point to a specific liver disease, a liver biopsy can
provide valuable information regarding staging, prognosis, and management. There are bad
interrelationships between clinical characteristics or status of serum liver enzymes and hepatic
histopathologic findings, but also patients with healthy status of liver enzymes may be diag-
nosed to have clinically advanced fibrosis or cirrhosis on histopathologic findings [64]. If the
patient has minor-state illness and is infected with genotype 1a or 1b of the hepatitis C virus, a
medical judgment may be made to delay treatment. If the patients have the above degree of
moderate disease, treatment will be commonly suggested. If the patients have a virological
reaction and acceptable adverse reactions with treatment, continued therapy would be firmly
encouraged. The cirrhotic findings on hepatic histopathology will indicate the need for extra
tests, such as upper endoscopic procedure to rule out esophageal varices and monitoring for
hepatoma with continuing assessment of serum α-fetoprotein and hepatic sonography [7]. In
alcoholic liver disease (ALD), the grade of the clinical symptoms and the severity of serum
liver enzymes elevation correlate poorly with the degree of liver pathology, particularly in
patients who continue to consume alcohol. The long-term prognosis depends upon the extent
of liver damage [65]. In patients with ALD as well as NASH, liver biopsy may demonstrate
hepatic fatty infiltration, ballooning degeneration of hepatocyte, Mallory’s bodies, and
hepatonecrosis, regardless of clinically severe fibrosis or cirrhosis [7]. In primary biliary cirrho-
sis (PBC), sequential liver biopsies may assist one to investigate the natural history, track the
responses of therapy, or identify a recurrence of the disease after liver transplantation [66, 67].
Liver biopsy allows a precise evaluation in approximately 90% of patients with obscure
disorders revealed on liver function tests [68]. The explanation of diverse courses that appear
in a transplanted liver including immune reaction, systemic or infectious complications, drug
◈ Diagnosis, grading, and staging of chronic hepatitis C or chronic hepatitis B.
◈ Diagnosis, grading, and staging of alcoholic liver disease, nonalcoholic steatohepatitis (NASH), or autoimmune
hepatitis
◈ Diagnosis of heavy metal storage disorders (e.g., hemochromatosis, Wilson’s disease)
◈ Evaluation of the cholestatic liver disease, primary biliary cirrhosis, and primary sclerosing cholangitis
◈ Evaluation of abnormal results of biochemical tests of the liver in association with serological workup that is negative
or inconclusive
◈ Use of hepatotoxic regimens (e.g., methotrexate therapy for psoriasis): monitoring
◈ Diagnosis of liver mass (e.g., cancer or unexplained lesions)
◈ Liver donor status before transplantation
◈ Evaluation of systemic illness (e.g., fever of unknown origin, inflammatory or granulomatous disorders)
◈ Hepatosplenomegaly of unknown cause: diagnosis
Table 1. Indication for liver biopsy (modified from Ref. [7]).
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toxic reaction, and the recurrence of primary disease necessitates a liver histological examina-
tion [69]. Liver biopsy can also provide the diagnosis of systemic diseases that can influence
the liver, such as sarcoidosis, lymphoma, acquired immune deficiency syndrome (AIDS), and
amyloidosis. The histopathological examination of the biopsy material is a subjective process;
therefore, diagnostic reproducibility at the 100% level is practically impossible. Intra-observer
and inter-observer agreement studies suggest that biopsy specimen size and observer experi-
ence (specialization, duration of practice, and academic practice) are important factors in
reducing the variation of assessment [8, 70]. Most studies of specimen adequacy have focused
on chronic hepatitis because it represents the most common indication for liver biopsy [71]. At
present, the most common suggestions for the precise assessment of the degree of fibrosis in
chronic hepatic diseases are that the size of biopsy tissue materials must be at a minimum of 20
mm in size and 1.4 mm in radius and must be retained at a minimum of 11 intact portal
tracts [72]. In addition, the type of biopsy needle is important, as suction needles tend to miss
the fibrous tissue of the septa, as opposed to cutting needles, thus providing the wrong
impression regarding the degree of fibrosis and the presence or absence of cirrhosis [73].
Finally, it should be kept in mind that biopsy specimens obtained from subcapsular locations
generally contain more fibrous tissue than deeper specimens taken perpendicular to the
hepatic surface. For many years, liver biopsy has been considered the gold standard for the
staging liver fibrosis [7]. For instance, in patients with chronic HCV, precise definition of the
liver fibrosis stage is the important parameter to assess the risk of disease progression and to
decide the need for immediate antiviral therapy [74]. Several standardized semi-quantitative
scoring systems have been proposed for the staging histological activity index (HAI) proposed
in 1981 by Knodell [75] and, more recently, the Ishak score [9] and the Metavir system [76]
(Table 2). All of these scoring systems have some limitations, being not linear and prone to
intra- and inter-observer variation and to sampling variability [77].
The Knodell score is a composite score that is based on histological assessment of periportal
and/or bridging necrosis, intralobular degeneration and focal necrosis, portal inflammation,
and fibrosis. The score ranges from 0 to 22, with higher scores representing more advanced
disease [75]. Knodell score is frequently used in trials of treatments for chronic hepatitis,
particularly HCV. The score is used to assure that baseline histologic features in treatment
groups are equally matched and to assess histologic changes after therapy. A limitation of the
Knodell score is that it combines inflammation and fibrosis to arrive at one composite score, so
it is relatively insensitive to changes in fibrosis. This is important because it is fibrosis, and not
inflammation per se, that leads to many of the sequelae of chronic liver disease. In addition,
patients may have the same Knodell score despite having markedly different degree of fibro-
sis. Also, the Knodell score is associated with high inter- and intra-observer variability. The
Metavir system is a semi-quantitative classification that consists of four intensity degrees of an
activity score (A0–A3) and a five-point scale of fibrosis (F0–F4) [8, 76]. In contrast to the
Knodell score, the Metavir system was specifically designed and validated for patients with
HCV [76]. The inter- and intra-observer reliabilities of the activity and fibrosis scores of the
Metavir system are similar to the Knodell score. The Ishak score is a modification of the
Knodell score that includes six stages of fibrosis [9]. This permits documentation of small
changes in fibrosis compared with the standard Knodell score, which has only four stages.
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This staging system has become widely used in clinical trials because of its ability to detect
mild changes in fibrosis [81]. The Scheuer system is a simple scoring system that separates
necrotic inflammation from fibrosis [78]. Histologic findings of portal inflammation, interface
hepatitis, and lobular inflammation are each assigned a score of 0–4. A separate score (0–4) is
assigned to the stage of fibrosis. Batts-Ludwig system is also known as the modified Scheuer
system [79]. This system is applicable to both chronic viral hepatitis and autoimmune hepatitis
and is more useful for assessing an individual patient’s liver biopsy for clinical care than
therapeutic trials. In addition, disease-specific scoring systems are also available, including
scoring systems for nonalcoholic fatty liver disease (NAFLD), ALD, primary biliary cirrhosis
(PBC), and primary sclerosing cholangitis (PSC). However, it is not common to encounter two
or more concurrent diseases in a liver biopsy specimen, no scoring systems are available that
specifically address these situations [81]. Absolute contraindication to liver biopsy includes
patient’s inability to remain still and to maintain brief expiration for the procedure, suspected
vascular lesion (e.g., hemangioma), bleeding tendency (e.g., INR >1.2 despite receiving vitamin
K, bleeding time >10 min), and severe thrombocytopenia (<50,000/mL). Relative contraindica-
tions include profound anemia, peritonitis, marked ascites, high-grade biliary obstruction, and
a subphrenic or right pleural infection or effusion. Nonetheless, percutaneous liver biopsy is
sufficiently safe to be performed on an outpatient setting [82]. Despite liver biopsy being the
standard test for an appropriate assessment of patients with chronic liver diseases, there are
several limitations of this including variable quality of liver biopsy specimens of <20 mm in
length which may be difficult to interpret. Therefore, larger caliber needles may yield better
than fine-needle biopsies [71]. Because of fluctuating disease activity, histologic changes
obtained at a single point in time may not reflect overall disease activity, which may vary. On
the other hand, one would often want to be aware of the progression of liver disease in order to
assess therapy response. Limitations entailed by repeat liver biopsy as regards potential
patient’s risks demand the development of new methods for liver fibrosis evaluation. The
features and limitations of liver biopsy are summarized in Table 3. On all these grounds,
noninvasive diagnostic tests (serum markers and imaging modalities) have been developed of
late mainly to assess liver fibrosis severity. The following pages attempt to describe available
information on the better-known serum markers as well as imaging techniques.
Fibrosis stage Knodell Ishak Metavir Scheuer Batt-Ludwig Laennec
No fibrosis 0 0 0 0 0 0
Fibrosis of some portal areas without septa 1 1 1 1 1 1
Fibrosis of most portal areas without septa 1 2 1 1 1 2
Portal fibrosis with few septa 3 3 2 2 2 3
Septal fibrosis without cirrhosis 3 4 3 2 2 3
Incomplete cirrhosis 4 5 4 3 4 4A
Cirrhosis 4 6 4 4 4 4B–4C
Table 2. Comparison between three scoring systems for liver fibrosis in chronic viral hepatitis (modified from Refs.
[19, 78–80]).
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4. Noninvasive assessment of liver fibrosis in patients with chronic liver
disease
Liver biopsy remains the “gold standard” of assessing hepatic fibrosis. However, it has limita-
tions, such as high cost, invasiveness, associated risk for complications, and sampling or
observer variability. Therefore, liver biopsy has recently been challenged by the development
of novel noninvasive modalities, including serum direct and/or indirect markers of hepatic
fibrosis, noninvasive modalities of predicting fibrosis and imaging techniques, including TE
(FibroScan), ultrasonography (US), computed tomography (CT), magnetic resonance imaging
(MRI), and thallium 201 per rectal scintigraphy (TI-201 test). As well as TE [85, 86], TI-201 test
is a relatively new technique for assessment of liver fibrosis or cirrhosis [87–91]. However, the
cost of the equipment may limit the use of TE in some institutions with limited resources. In
the past decade, several noninvasive methods for assessing hepatic fibrosis have been
published, resulting in more noninvasive tests than histologic scoring systems. The noninva-
sive tests were introduced to estimate the likelihood of advanced liver fibrosis in patients with
chronic viral liver disease at presentation, and on follow-up to assess fibrosis regression in
post-treatment period [92]. These tests were later applied in ALD [93, 94] and NAFLD [95, 96].
Our previous studies on the clinical value of the TI-201 test in chronic liver disease may be
useful in differentiating chronic hepatitis from cirrhosis and prediction of its prognosis for the
management of disease [90, 91, 97, 98]. The first important clinical topic in the assessment of
new diagnostic methodologies for evaluation of liver fibrosis is its validation against the
present clinical gold standard, liver biopsy, to calculate sensitivity, specificity, and negative-
(NPV) and positive-predictive values (PPV). The standard statement of the efficiency of modal-
ities is to examine the area under the receiver operator characteristic curve (AUROC), which
plots the sensitivity over 1-specificity using liver biopsy as the reference [17]. The AUROC
Liver biopsy Noninvasive methods
Pros • Gold standard to assess fibrosis
• Direct observation and quantitative assessment of fibrosis,
inflammation, and steatosis
• Different stage by different scoring systems
• Diagnosing different forms of liver disease
• Accurately assessing progression of liver disease or the
effect of therapy
• Noninvasive
• No complications and no contraindica-
tions
• Inter-laboratory reproducibility
• High applicability and wide availability
for repeated assays
• Reasonable cost
• Accurate assessment of cirrhosis and
minimal/no fibrosis
Cons • Invasive
• Sampling variability/evaluation of a tiny part of the
whole organ (1:50,000)
• Intra- and inter-observer variability
• Unsuitable for repeated assays
• Risk of complications, rare major complications,
morbidity and mortality
• High cost
• Less accurate for intermediate fibrosis
stages
• False-positive values
• Scores may change in different disease
stages
• Unsuitable for diagnosing liver disease
• Not quantitative
• “Grey zone” (intermediate results in
14–33% of cases)
Table 3. Pros and cons of liver biopsy and noninvasive methods for the evaluation of liver fibrosis in chronic liver disease
(modified from Refs. [83, 84]).
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indicates the probability that a test will correctly rank two randomized patient groups, one
with a liver biopsy considered “normal group” and the other “diseased group” [99, 100].
Because liver biopsy itself is not a perfect gold standard, a perfect test will never reach
maximal value (1.0) [17]. According to a range of accuracies of the biopsy and a range of
prevalence of significant disease (that influence the AUROC), an AUROC of >0.90 in the most
favorable scenario cannot be achieved when assessing the so-called “significant fibrosis” even
for a perfect marker [99, 101]. This is important for several reasons. First, studies have already
shown that these maximal AUROC values have been reached for surrogate markers, especially
when assessing cirrhosis versus non-cirrhosis, suggesting that these surrogate markers may be
at least as good as liver biopsy in the diagnosis of cirrhosis [102]. Second, some reports suggest
that a definitive method for assessing the performance of surrogate markers would employ a
clinical end point rather than biopsy as gold standard [101]. The AUROC values may also
depend on the biopsy tissue size and fragmentation [103] as well as the incidence of each stage
of fibrosis within the studied population (e.g., the spectrum bias) [104]. Indeed, if extreme
stages of fibrosis (F0 and F4) are overestimated in a population, the sensitivity and specificity
achieved will automatically be higher than in a population that included only patients with
near stages of fibrosis (F1 and F2). Several strategies of prohibiting the “spectrum bias” have
been suggested including the realignment of AUROC by the DANA method that define
advanced (F2–F4) and non-advanced fibrosis (F0–F1) [104] or the Obuchowski measure that is
multinomial version of the AUROC [105, 106]. Today, noninvasive methods are widely avail-
able. Their most advantages are the absence of contraindication and dangerous complications
for the patients, and their reproducibility [107]. In contrast to liver biopsy, many noninvasive
methods can effectively evaluate the extent of fibrosis in the whole organ and not only in a part
of it. Their potential ability to identify and differentiate between advanced fibrosis stages, the
high specificity and sensitivity to diagnose cirrhosis, and their easy application makes them a
useful tool in daily clinical practice. Many liver fibrosis experts would therefore consider
noninvasive fibrosis tests with an AUROC of 0.85–0.90 to be as good as liver biopsy for
diagnosis and staging for liver fibrosis [108]. The role of noninvasive diagnostic tests becomes
more significant because their diagnostic accuracy can be increased if they are combined, that
is, a serological panel may be used in conjunction with an imaging technique [90, 99, 109].
Features of ideal noninvasive markers of liver fibrosis are summarized in Table 4.
4.1. Serological markers of liver fibrosis
The clinical need for good noninvasive markers of fibrosis is underlined by the marked
increase in the number of reports in this area in recent years. A large number of the serological
markers of liver fibrosis have been assessed for the noninvasive evaluation of liver fibrosis and
◈ Liver specific
◈ Levels not influenced by alterations in liver, renal, or reticuloendothelial function
◈Measurement of one or more of the following processes: Stage of fibrosis, imbalance of activity of ECM (fibrogenesis
vs. degradation)
◈ Easy to perform
Table 4. Features of an ideal marker of liver fibrosis (modified from Ref. [108]).
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are broadly categorized into two groups (direct and indirect) [107]. First, we will refer to direct
markers of fibrosis that are thought to directly reflect ECM turnover. Fields in which these
methods may have clinical or investigational values involve both the noninvasive method for
staging of liver fibrosis but they may also be useful for monitoring the behavior of fibrogenesis
and ECM metabolism. Therefore, such assays may be valuable in forecasting fibrotic disease
deterioration as well as the efficiency of treatment. Second, there are those that reflect changes
in hepatic function but do not directly reflect ECM turnover, for instance, platelet count,
coagulation studies, and evaluation of liver enzymes, the so-called indirect markers of liver
fibrosis. Researches and developments of these markers have largely focused on the diagnosis
of cirrhosis, but more recent researches have emphasized the availability of these markers to
assess patients with more advanced fibrosis and hence may be valuable in guiding treatment
decisions and prediction of complications of liver cirrhosis [90, 108].
4.1.1. Direct markers of liver fibrosis
Direct markers of liver fibrosis include serum markers, which have been shown to be, or are
thought to be, directly involved in the deposition or degradation of ECM. The best-validated
marker is hyaluronic acid (HA), a glycosaminoglycan synthesized by HSCs [110]. HA levels
correlate with fibrosis in ALD [111] and chronic viral hepatitis [112, 113] and a highly negative
score may be used in clinical practice as a reliable index for exclusion of liver fibrosis. Amino-
terminal propeptide of type III collagen is a marker associated with collagen deposition and its
level is increased in acute and chronic hepatic diseases [114]. TIMPs (TIMP-1 and -2), on the
other hand, are associated with the procedure of collagen degradation, which is progressive to
fibrosis consequence [114]. The direct markers include several cytokines and markers of matrix
turnover (Table 5). The circulating retention times of these molecules are short, so levels may
reflect the behavior of ECM turnover. Since ECM turnover is related to both new ECM
accumulation and degradation and rebuilding of formed ECM, circulating levels probably
exhibit both the activity of the fibrogenesis and the total amount of ECM rebuilding [108]. This
phenomenon is identified by at least three properties. First, circulating amounts of these
markers are often most increased in situations with rapidly processing fibrosis (e.g., advanced
ALD or more active viral hepatitis) and may be high ahead of the significant accumulation of
ECM [113, 115]. Second, circulating ECM levels tend toward a decrease in reaction to therapy
of the underlying illness, often before any perceptible decrease in the stage of fibrosis [116].
Third, in chronic liver diseases, elevations of several, but not all of these markers associate
independently with the stage of fibrosis, rather than with either serological or histopathologi-
cal findings of inflammatory reaction [112, 117, 118]. In some studies, however, levels of these
markers correlated more strongly with the degree of histopathological inflammation or serum
liver enzymes [119]. The observation that markers of ECMmetabolism are increased in parallel
with markers of liver inflammation and necrosis may reflect the importance of these processes
in up-regulating fibrogenesis. Direct markers of fibrosis can also be categorized according to
their molecular structures. These include (a) collagens: procollagen I and III, propeptides
released into the circulation during matrix accumulation and rebuilding. Type IV collagen,
which is secreted during interstitial filament metabolism, reflects matrix depletion and rebuild-
ing; (b) glycoproteins and polysaccharides including HA [120], laminin [121], tenascin, and
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YKL-40 [122]; and (c) collagenase and their inhibitors, include the MMPs and TIMPs, and
cytokines involved in liver fibrosis, the best studies of these is TGF-β. Others, including PDGFs
and the antifibrotic cytokine IL-10, have been less well evaluated [108]. The greatest clinical
utility of HA may be its ability to exclude patients with significant fibrosis and cirrhosis [112].
4.1.2. Indirect marker and combined panels of liver fibrosis
Indirect markers of fibrosis are simple routine blood tests reflecting alterations in liver function
but not directly representing ECM homeostasis. These biomarkers include indices related to
portal hypertension (platelet count and spleen size), liver synthetic parameters (i.e., albumin),
liver enzymes such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
[123], AST/ALT ratio [124, 125], bilirubin, prothrombin index (PT) [126], γ-glutamyl transferase
(γ-GT), and apolipoprotein A1(apo-A1). They can be used in combination to produce sophisti-
cated serological panels such as PGA index (prothrombin time, γ-GT, and apo-A1) [127–129]
and APRI (AST to platelet ratio index) [130, 131]. PGA is one of the first biological indexes used
for the noninvasive detection of cirrhosis in ALD patients [127]. APRI is based on serum AST
level and platelet [131]. It is calculated as (AST/upper limit of normal*)  100/platelet count
and has been extensively studied in patients with HCV or ALD (*adjusted according to the
reference values of each laboratory) [107, 132]. PGA index was subsequently modified to the
PGAA index by the addition of α2-macroglobulin which resulted in some improvement in its
performance (PGAA) [128]. Analysis of studies of indirect markers of fibrosis reveals several
features, which are applicable to routine clinical practice. First, in viral and NAFLD, an AST/
ALT ratio of greater than 1 is frequently associated with progressive liver fibrosis or cirrho-
sis [133–135]. Second, both components of the PGA index such as γ-GT and thrombin index
are markers of advanced liver fibrosis and can be used to discern patients with more advanced
liver fibrosis. Indeed, the prothrombin index has been carried out alike or better than
specific other markers of liver fibrosis [117, 136]. It should be emphasized that these markers
represent liver dysfunction or structure rather than the disturbance of normal ECM metabo-
lism (Table 6) [108].
4.1.3. Indices/algorithms combining indirect and direct markers of liver fibrosis
The limitations of each marker to assess liver fibrosis have led to the development of more
sophisticated algorithms or indices combining the results of panels of markers that substan-
tially improved diagnostic accuracy in noninvasive evaluation of liver fibrosis (Table 7).
Markers of deposition Markers of degradation Unknown roles
◈ Procollagen I C-terminal ◈ Procollagen IV C peptide ◈ Hyaluronic acid(HA)
◈ Procollagen III N-terminal ◈ Procollagen IV N peptide (7-S collagen) ◈ Laminin
◈ Tenascin ◈ Collagen IV ◈ YKL-40 (Chondrex)
◈ TIMPs ◈ Undulin
◈ TGF-β ◈MMPs
Table 5. Direct markers of ECM turnover (deposition vs. degradation) (modified from Ref. [108]).
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Scores/algorithms Description
FibroTest [137] • Most validated algorithm and consider patient age and gender
• Five parameters: apo-A1, α2-macroglobulin, γ-GT, total bilirubin, haptoglubin.
Hepascore [147] • Four parameters: bilirubin, γ-GT, HA, TIMP-1, α2-macroglobulin), age, and
gender.
• Prediction with AUROC 0.81 in significant fibrosis and 0.88 for cirrhosis
Fibrospect [148] • 3 parameters: serum HA, TIMP-1, α2-macroglobulin
• Moderate or severe fibrosis versus no fibrosis
Fibrometer [149] • Six parameters: platelet count, prothrombin time, AST, α2-macroglobulin, HA,
BUN
• Prediction of severe fibrosis in chronic viral hepatitis
ViraHep C model [150] • Probability ¼ 1/(exp[y]) þ 1, y ¼ 5.17 þ 0.2xrace þ age(years) þ 1.19  ln
(AST, IU/L) –1.76ln(platelet, 103/mL) þ 1.38ln(AP, IU/L) for severe fibrosis
in chronic hepatitis C
• Dependent on race (AA, African American ¼ 0, CA, Caucasian American ¼ 1)
Glycocirrhotest [151] • Detection of compensated cirrhosis with 100% specificity and 75% sensitivity.
• Follow-up of chronic liver diseases patients without repeated biopsy
Fibrosis Probability Index (FPI)
[152]
• Multivariate logistic regression analysis identified age, AST, total cholesterol
level, insulin resistance (by homeostasis model), and past alcohol intake as
independent predictors of significant fibrosis.
• 96% sensitivity and NPV 93% at a score of ≥0.2 versus 94% specificity and PPV
87% at a score of ≥0.8.
• Probability of significant liver fibrosis in patients with chronic HCV infection
and useful guide to make decision for need of biopsy.
Goteborg University Cirrhosis
Index (GUCI) [153]
• Multivariate logistic regression analysis between fibrosis stage (ref. as Ishak
stage)
• GUCI formula: normalized AST  prothrombin-INR  100/platelet count(
109/L)
• 80% sensitivity and 78% specificity for cirrhosis with NPV 97% and PPV 31%
Forns score [154] • 7.811–3.131ln(PT) þ 0.781ln(γ-GT) þ 3.467ln(age) – 0.014 (cholesterol)
• Validation in patients with CHC as well as nonviral chronic hepatitis
Direct serum markers Indirect serum markers/combined panels
◈ HA ◈ Liver enzymes (ALT, AST)
◈ Laminin ◈ AST/ALT
◈ YKL-40 ◈ γ-GT
◈ Procollagen type III ◈ Platelet count
◈ PIIINP ◈ Albumin
◈MMP-1 and -2 ◈ Bilirubin
◈ TIPMs ◈ PGA
◈ TGF-β ◈ APRI
Abbreviation: TIMP, tissue inhibitors of metalloproteinases; MMP, matrix metalloproteinase; ALT, alanine aminotrans-
ferase; HA, hyaluronic acid; APRI, aspartate aminotransferase/platelet ratio index; PIIINP, Procollagen III amino terminal;
γ-GT, γ-glutamyl transpeptidase.
Table 6. Serum noninvasive marker of liver fibrosis (modified from Refs. [19, 84]).
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In most studies, indices have been validated against the current clinical gold standard, liver
biopsy, using as expression of their effectiveness the AUROC with optimal value being as close
as possible [99]. The first proposed index was based on a parented mathematical formula
combining five variables (total bilirubin, γ-GT, haptoglobin, α2-macroglobulin, and apo-A1)
[137] and the results of this test were ranged from 0 to 1.0, using Fibrotest as a reference. In the
initial report, a very low score (<0.1) allowed the exclusion of significant fibrosis with a 100%
negative-predictive value (NPV), whereas a moderate high score (>0.6) allowed the diagnosis
of significant fibrosis with a 90% positive-predictive value (PPV), using liver biopsy as a
reference. Overall, liver biopsy could have been avoided in 46% of the patients from that study.
Fibrotest has been primarily used for patients with chronic viral hepatitis and is now exten-
sively evaluated in the patients with chronic hepatitis C [109, 138, 139] but also in other cases,
such as hepatitis B [140, 141], HCV and HIV coinfection [142], NAFLD [143], ALD [93], and
renal-transplanted patients with chronic HCV [144]. The recent meta-analysis that pooled 7985
subjects (with analysis of individual data in 3282) with both Fibrotest and biopsy (HCV, 4600;
HBV, 1580; NAFLD, 267; ALD, 524; mixed form, 1014) and the mean standardized AUROC for
Scores/algorithms Description
ELF score [155] • Combination of HA, TIMP-1, amino-terminal propeptide of collagen III colla-
gen.
• Useful tool in various chronic liver diseases (e.g,. ALD, NAFLD)
APRIþFibrotest [140] • Improvement of diagnostic accuracy of Fibrotest for detection of significant
fibrosis (≥2 by Metavir) and cirrhosis (F4) in CHC patients.
• Accuracy of SAFE biopsy for significant fibrosis and/or cirrhosis: above 90%
BAAT score [156] • Index for NAFLD fibrosis (BMI, age, ALT, TG levels)
• 4 features, assigning 1 point for each of the following: BMI ≥28 kg/m2, age ≥50
years, ALT ≥twice the normal values, and TG ≥1.7 mmol/L.
• A score of 0 or 1 excludes significant fibrosis with NPV of 100%
BARD score [157] • Combination of three variables (AST/ALT ratio, BMI, Type 2 DM)
• (BMI ≥28 ¼ 1, AST/ALT ratio ≥0.8 ¼ 2, diabetes ¼ 1, score ≥2, odds ratio for
advanced fibrosis ¼ 17)
• The variables such as obesity, diabetes, and age influence the score, resulting in
a very low PPV and validated in a cohort of NAFLD
NAFLD fibrosis score [158, 159] • Logistic formula: –1.675þ0.037age(years)þ0.094BMI(kg/m2)þ1.13
impaired fasting glucose/diabetes(yes ¼ 1, no ¼ 0)þ0.99AST/ALT ratio-
0.013platelet count(109/L)– 0.66  albumin (g/dL)
• Values ≤1.455: no advanced fibrosis vs. ≥0.676: advanced fibrosis
FIB-4 score [160] • 90% NPV in excluding and a satisfying 80% PPV in diagnosing fibrosis.
• Calculating formula: (age  AST)/(platelet count(109/L) 
ffiffiffiffiffiffiffiffiffiffi
ALT
p
• NAFLD score and FIB-4: determination of necessity of liver biopsy in NAFLD
P-value [98] • 3 parameters: ALT/AST ratio, prothrombin time, H/L ratio
• P-value ¼ exp[y]/(exp[y]þ1), y ¼ 3.3431–0.8160ALT/AST–
0.343PTþ2.693H/L ratio
• P < 7.0: non-cirrhotic patients (96.2%)
Abbreviation: AP, alkaline phosphatase; NPV, negative-predictive value; PPV, positive-predictive value, CHC, BMI, body
mass index; H/L ratio, heart/liver uptake ratio; γ-GT, γ-glutamyl transpeptidase.
Table 7. Combined scores/algorithms for evaluation of liver fibrosis.
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diagnosing significant fibrosis was 0.84 (95% confidence interval: 0.83–0.89), without differ-
ences between causes of liver disease. Therefore, Fibrotest have been used as an alternative to
liver biopsy for the first-line assessment of fibrosis and common chronic liver diseases, namely
HCV, HBV, NAFLD, and ALD [145]. One of the important issues of these algorithms is that in
individual patients they cannot reliably differentiate the intermediate stages of fibrosis. Finally,
in patients with chronic HCV, the application of these algorithms or indices can confirm or
exclude fibrosis in less than 40% of patients [146].
4.1.4. Combination of indices and algorithms for assessment of liver fibrosis
In order to increase diagnostic accuracy, new approaches using stepwise algorithms combining
continually different indices have been proposed in patients with chronic hepatitis C [161] and
B [140]. For instance, one group was able to identify significant fibrosis with high diagnostic
outcome above 94% diagnostic accuracy by APRI as screening procedure, followed by
Fibrotest in APRI non-classified cases and prohibiting liver biopsy to patients classified F0–F1
by noninvasive procedures. Cirrhosis could also have been recognized with 95% diagnostic
accuracy applying a similar algorithm by the combination of APRI and Fibrotest (Figure 2). On
the whole, liver biopsy could have been prevented in approximately 50 and 80% of patients for
the diagnosis of severe fibrosis and cirrhosis in patients with chronic hepatitis C, respectively.
Other groups have proposed alternative algorithms combining Fibrotest and APRI either
with [162] or without Forns index [146]. Otherwise, high diagnostic accuracy for the evaluation
of significant fibrosis and cirrhosis has been reported for the combination of Fibrotest with
Fibroscan that is based on the assessment of hepatic stiffness by TE [22, 109]. However, this
method requires the availability of complex equipment, with limited access and costs that most
likely exceed those of their more simple and accessible algorithms [161].
Several noninvasive markers of liver fibrosis have been represented but their application in
substitute for liver biopsy may still remain controversy and is not generally acceptable due to
still insufficient diagnostic performance. In fact, some of these methodologies such as APRI
and Forns index remain in many cases unclassified group and all of them are not over 80–85%
diagnostic performance [131, 139, 163, 164]. As a consequence, many patients still need to have
a liver biopsy taken, and in those classified without liver biopsy, misdiagnosis is expected to
occur in at least 15–20%, a figure that is considered inadequate by many clinicians [165, 166].
Most of them, such as APRI and Forns index, are not able to identify individual stages of
fibrosis. APRI cannot be completely standardized due to the variability of measurement and
normal ranges of AST in different laboratories [167]. Since the diagnostic performance of
described noninvasive markers is variable depending on the stage of fibrosis and other
patients’ characteristics, they can be used to reduce rather than completely substitute the need
for liver biopsy. Even though many studied have been shown that Fibrotest had the best
performance when compared to other noninvasive methods, none of the investigated nonin-
vasive markers of liver fibrosis has adequate accuracy for universal use instead of liver
biopsy [140]. And, one of the major critical points of the clinical application of serum markers
and indices of liver fibrosis is that they are not regularly useful in most clinical situation.
Another clinical point of these markers is that they are liver nonspecific and may be influenced
by changes of their level; for example, HA levels increase after the meal [168] or in senile
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patients with chronic inflammatory states such as rheumatoid arthritis [169]. Also, the repeat-
ability of assessments of several biomarkers included in direct serum markers, such as AST
levels or platelet count, is doubtful [170]. The effect of serum lipid levels caused by
anticholesteremic agents on the Forns index was taken into consideration. Finally, when
applying Fibrotest in clinical situation, the evaluation should consider each of the five markers
individually in order to escape false-positive outcomes related to hemolysis (low hepatoglobin
level), Gilbert syndrome (high bilirubin level), or false-negative outcomes related to inflamma-
tory reactions [171]. However, a panel that combines proteins and proteinases of the ECM has
been proposed and the results are promising [155]. The combined use of some of these markers
with the aim of reducing rather than completely abolishing liver biopsy may represent a
rational and more convincing approach [172]. In a large-scale multicenter study, the diagnostic
accuracy of a stepwise combination of two well-studied noninvasive markers of fibrosis (APRI
and Fibrotest) was followed by liver biopsy in only a subset of cases [171]. This approach,
called SAFE (sequential algorithm for fibrosis evaluation) biopsy, has been built up with
double goal of detecting both severe fibrosis and cirrhosis and has here been confirmed to
assure >90% diagnostic accuracy in comparison with respect to liver biopsy as the gold
standard with <2% underestimation of the stage of liver disease as derived from NPV. The
Figure 2. Proposed best algorithm for the detection of significant fibrosis and cirrhosis using APRI and Fibrotest in
patients with chronic hepatitis C and B with diagnostic accuracy (modified from Refs. [90, 159]).
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SAFE biopsy may be particularly useful for screening HCV-infected patients in whom an
immediate approach with liver biopsy is particularly problematic or questionable [173]. Using
two algorithms (Fibrotest and APRI), liver biopsy could be avoided in 50% of cases for the
diagnosis of significant fibrosis and in 70% of cases for the identification of cirrhosis [174].
4.2. Imaging modalities and combinations with other markers for the
diagnosis of liver fibrosis
4.2.1. Transient elastography (TE)
Liver fibrosis can be staged using one-dimensional ultrasound TE (Fibroscan) [22], which is the
most widely used imaging method for noninvasive and rapid measurement of hepatic tissue
stiffness. Many studies have evaluated the diagnostic accuracy of TE for diagnosing cirrhosis
with specificity and sensitivity approaching 90%. The accuracy for liver fibrosis detection is
lower, with sensitivity and specificity approaching 70–80% [102, 175, 176]. Because both adi-
pose tissue and the presence of fluid may influence the velocity of shear wave [107], obesity,
ascites, acute inflammation, liver congestion, and elevated portal vein pressure may reduce TE
accuracy. Furthermore, a falsely increased liver stiffness, due to postprandial increase in portal
vein pressure, has been observed [177, 178]. Comparison of TE with biopsy results has pro-
vided that cut-off values can be demonstrated to differentiate mild and moderate fibrosis from
advanced fibrosis and cirrhosis, with validation tests showing variable performance and with
greatest statistical significance being ensured in the distinction of cirrhosis from mild fibrosis
(AUROC F ¼ 4 (0.94), sensitivity F ≥ 2 (85%), specificity F ≥ 2 (91%)) [179, 180]. Investigations
have applied various best stiffness cut-off values, making comparison between researches.
Generally, advanced fibrosis is more likely with higher cut-off values (Table 8) [181, 182]. The
optimal cut-off value is 14.6 kPa for the detection of cirrhosis, but a cut-off value of 10.0 and
14.1 kPa was adequate to achieve 95% sensitivity and specificity in their HCV patients with
cirrhosis [183]. Otherwise, the performance of TE was low for discriminating mild from
significant liver fibrosis [184] and Spearman’s correlation coefficient between the elasticity
scores using real-time TE and histopathological fibrosis stage was low at 0.48 [185]. However,
TE was more useful for the identification of advanced fibrosis and their necroinflammatory
activity influences TE measurements in patients without cirrhosis [186] and might be
overestimated liver fibrosis when ALT is elevated [187]. Some reports were shown that good
correlation between TE and fibrosis exists, but data on TE in an Asian cohort show only 8% of
patients having limited HCV [188]. Liver stiffness measurement (LSM) by TE is a reliable
predictor of liver fibrosis in Indian patients with chronic hepatitis C and B. LSM is superior to
APRI for noninvasive diagnosis of hepatic fibrosis and cirrhosis, and high bilirubin (10.5 mg/dL)
and Ishak HAI grade (>11) were independent predictors of discordance between liver biopsy and
LSM [189]. Liver stiffness has also been revealed to have good correlation with steatosis, necrotic
inflammatory activity and hepatic iron accumulation as well as fibrosis [190]. TE is restrictive,
however, by its impossibility to perform in patients with ascites and patients with narrow
intercostal spaces or morbid obesity. Advantages of TE include a short procedure time (<5 min),
immediate results, and the ability to perform the test at the bedside or in an outpatient clinic.
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4.2.2. Magnetic resonance elastography (MRE)
MRE is a noninvasive method of measuring the viscoelastic properties of the liver and
evaluate liver stiffness by measuring the propagation of mechanical waves [194]. MRE indi-
cated that patients with hepatic fibrosis have higher LSM than normal volunteers [195] and
that those with mild fibrosis were able to be distinguished from those with moderate or
advanced fibrosis, with a mean hepatic shear elasticity being 2.24, 2.56, and 4.68 kPa in
patients with F0–F1, F2–F3, and F4 fibrosis, respectively [196]. MRE is superior to TE because
of its ability to scan the whole organ and its application in patients with ascites or obesity.
MRE was accurate in liver fibrosis staging and superior to biochemical testing with APRIs in
patients with chronic HBV and HCV infection [197, 198]. These findings suggest that nonin-
vasive MRE potentially has a role in determining the treatment and the prognosis of patients
with chronic liver disease because it enables substantial and advanced fibrosis to be readily
diagnosed. More particularly, MRE might be useful in the selection of patients with liver
fibrosis who should either be treated (score of ≥F2) or undergo surveillance for portal hyper-
tension and hepatocellular carcinoma (score of ≥F3) [197]. Antiviral treatment should be
considered in patients with liver stiffness values of ≥2.8 kPa [199]. The main drawbacks are
the high cost and complexity of the method that is too procrastinating for daily clinical
Etiologies Patients (n) Metavir score Cut-offs AUROC
(kPa)
SE (%) SP (%) CC (%)
F ≥ 2 (%) F 4 (%)
HCV [109] 183 74 7.1 0.83 67 89 73
25 12.5 0.95 87 91 90
HCV [181] 251 65 8.6 0.79 56 91 68
19 14.6 0.87 86 96 94
HCV [186] 150 56 7.8 0.91 83 82 83
19 14.8 0.98 94 92 92
HCV [190] 324 65 7.4 0.86 76 84 79
21 11.9 0.94 87 91 90
HBV(CV)[179] 228 62 8.3 0.93 90 32 57
50 14.0 0.96 78 98 88
HBV [192] 173 50 7.2 0.81 70 83 76
8 11.0 0.93 93 87 94
HBV [193] 284 42 5.2 0.78 89 38 59
10 12.9 0.85 52 93 89
Abbreviations: AUROC, area under the receiver operator characteristic curve; CC, correctly classified: true positive and
negative; HBV, chronic hepatitis B; HCV, chronic hepatitis C; SE, sensitivity; SP, specificity.
Table 8. Diagnostic performance of TE for significant fibrosis (F ≥ 2) and cirrhosis (F4) in patients with Hepatitis B or C
(modified from Refs. [191]).
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practice. MRE values may be affected by the increased portal vein pressure following a meal
similar to TE [200].
4.2.3. Acoustic radiation force impulses (ARFI)
ARFI use conventional hepatic ultrasonography to assess liver stiffness [199, 201]. ARFI uses
short duration of acoustic pulses that produce mechanical excitation. The speed of the
produced waves correlates directly with the extent of liver fibrosis and results are expressed
in m/s. For fibrosis quantification, the “Virtual Touch (VT) tissue quantification” application
was used, allowing for the measurement of SWV (shear wave velocity, m/s) within the
interest area chosen by the examiner, according to principles. The higher the tissue stiffness
shows, the higher the SWV produces [202]. The theoretical advantage of ARFI as compared
to TE is its implementation on an ultrasound device, via additional software imaging control
and detection algorithms, thus allowing the visualization of B-mode, color Doppler mode,
and ARFI images with same equipment [201]. Advantages of this technology include the
ability to select the area to be assessed, avoiding large vessels or ribs [107] and the fact that
steatosis does not influence the accuracy of the procedure. Otherwise, ARFI and TE are
influenced by high ALT levels. In European patients with chronic hepatitis B and C, ALT
values between 1.1x and 5xULN had only limited influence on ARFI values. The best cut-off
values for predicting significant fibrosis and cirrhosis were similar in patients with moder-
ately elevated ALT levels [203].
4.2.4. Real-time sonography-based elastography (RTE)
RTE is a new method for the measurement of tissue elasticity different from TE. The echo
signals are captured in the real time, while the probe slightly compresses or relaxes the body
through freehand operation. Many clinical researches indicated that RTE could allow a high
accuracy on the differential diagnosis of superficial focal pathological lesion such as mam-
mary gland tumors, thyroid tumors, and prostate tumors [204, 205]. This method estimates
the velocity of a shear wave through the liver using US and results are expressed in kPa. The
diagnostic accuracies expressed as AUROC were 0.75 for the diagnosis of significant fibrosis
(F ≥ 2), 0.73 for severe fibrosis (F ≥ 3), and 0.69 for cirrhosis. For a combined elasticity-
laboratory scores (platelet count and γ-GT), AUROCs were 0.93, 0.95, and 0.91, respectively.
Therefore, RTE is a new and promising sonography-based noninvasive method for the
assessment of liver fibrosis in patients with chronic viral hepatitis [185].
4.2.5. 2D-Shear wave elastography (2D-SWE)
2D-SWE combines ultrasound images with radiation force induced into the liver. 2D-SWE can
measure shear waves propagation in real time [16]. Advantages of 2D-SWE (m/s or kPa)
include good applicability and adjustable region of interest depending on the operator [84].
Its failure rate is significantly lower than that of TE [206–208], particularly in patients with
ascites [207, 208], but not in obese patients when the XL probe is used for TE (10.4 vs. 2.6%,
respectively) [209]. In a pilot study in 121 patients with chronic hepatitis C (Metavir, 41% F0/
F1, 27% F2, 12% F3, and 20% F4), AUROCs of 2D-AWE for the diagnosis of significant fibrosis
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and cirrhosis were 0.92 and 0.98, respectively [206]. Sensitivities and specificities were 85 and
92% for the diagnosis of significant fibrosis using a cut-off of 7.1 kPa, and 97 and 93% for the
diagnosis of liver cirrhosis using a cut-off of 10.1 kPa. Therefore, 2D-SWE is a promising
technique that is currently under investigation. It seems to be at least equivalent to TE and
pSWE/ARFI for noninvasive staging of liver fibrosis in viral hepatitis [16].
4.2.6. Sonography-based imaging
US imaging has been used to noninvasively evaluate the severity of liver fibrosis in patients
with chronic HCV. Results vary with some studies showing associations between US score and
diagnosis of cirrhosis with various sensitivities (87.5–100%) and specificities (81.5–93.5%)
[210, 211]. The application of US to assess liver fibrosis was used by calculating a fibrosis
extraction ratio (FER) (fiber volume/total volume), which was able to distinguish F0/F1 from
≥F2 fibrosis with a sensitivity of 55% in the HCV cohort [212]. In sonography, contrast-
enhanced sonography is based on intravenous injection of specifically sized microbubbles,
transferred with a shell of protein or biopolymers that facilitate their sonographic imag-
ing [213]. Some report studied the hepatic vein transit time (HVTT) for grading liver disease
using a microsound microbubble contrast agent as a tracer. This study also applied Doppler
sonography to make a decision for several indices to assess portal vein congestive index, but
found that there was no significance. HVTTwas significantly shorter in cirrhotic patients than
in non-cirrhotic patients (p < 0.001) and distinguished between these patients with high accu-
racy [214]. Therefore, unenhanced Doppler ultrasound is not reliable in the discrimination of
varying degrees of fibrosis, but that results can be improved with additional measurement
such as heart pulsation at the liver surface and portal venous flow measurements. Color
Doppler is a noninvasive method for assessing portal hemodynamics. In the study for portal
hemodynamics by color Doppler and gastric mucosal blood flow (GMBF) by laser Doppler
velocimetry in patients with cirrhosis, portal venous blood flow (PVBF), portal flow velocity
(PFV), and GMBF were all significantly slower in cirrhotic patients and PVBF and PFV were
lower in Child’s class B/C than in class A [215]. A statistically significant difference has been
shown in all US markers between patients with and without cirrhosis, but sensitivity and
specificity were significantly increased when evaluation of the transmission of heart pulses on
the liver surface area included as part of the US test a sensitivity of 85 versus 55% and a
specificity of 93 versus 86%, respectively [216].
4.2.7. Per rectum TI-201 scintigraphy (TI-201 test)
A complete understanding of the hepatic disease requires the evaluation of portal circulation,
which allows for more appropriate treatment and follow-up of patients. During the last six
decades or more, several clinical reports have investigated portal circulation by radioactive
tracers [87, 88]. These reports have been established that TI-201 test allows us to understand
the portal circulation, and a new method using TI-201 distribution patterns seems to be useful
in evaluating the portosystemic shunt (heart/liver uptake ratio, H/L ratio), which can develop
to varying extents in liver cirrhosis and positive correlation to portal pressure in patients with
chronic hepatitis [87–89, 217]. Our previous studies on the clinical value of H/L ratio in chronic
liver disease may be useful in differentiating chronic hepatitis from cirrhosis and the prediction
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of its prognosis for the management of disease [97]. Noninvasive test such as maximal removal
rate of indocyanine green and H/L ratio, as well as ALT/AST ratio, prothrombin time, and
platelet count, may be used to evaluate the progression of chronic liver disease without liver
biopsy [98] as well as progression of variceal bleeding without an endoscopy in biopsy-proven
patients with cirrhosis [218]. However, because most serum markers except H/L ratio may be
changeable by medical treatment of chronic liver disease, serum markers are not suitable for
monitoring long-term outcomes of patients with cirrhosis. On assessing the predictive values
of H/L ratio for decompensation during the follow-up period of 45.5 months in 107
patients [90], the last visiting value of H/L ratio provided a strongly reliable predictor of
decompensation with an odds ratio estimate of 14.4, an AUROC of 0.825, a cut-off of 0.4, a
sensitivity of 73.1%, and a specificity of 71.6% (Figure 3).
5. Conclusion and perspectives
There is an urgent need to pursue the development of noninvasive tests in addition to a liver
biopsy for the staging of fibrosis. The area of liver fibrosis and cirrhosis has been extensively
Figure 3. I. Typical scintigrams after administration per rectum of 18.5 MBq 201TI and H/L ratio versus time profiles in a
decompensated patient (A, B) and compensated patient (C, D) at the first and last visits. On the left I (AYD) are
scintigrams after administration per rectum of 18.5 MBq 201TI in each patient (ROI g1, liver area vs. ROI g2, heart area)
and on the right I (AYD) are time-activity curves for the H/L ratio in each patient. ROI, regions of interest. II. Mean H/L
ratio of the first visit when the patient is diagnosed with cirrhosis and the last visit before the development of decompen-
sation in patients with liver cirrhosis. III. ROC curve and cut-off point of last visit H/L ratio (Q0.4) (permission from Ref.
[90]).
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studied during the few decades. As a result of growing understanding of liver injury and
fibrosis, a number of noninvasive tests for fibrosis that are accurate and replace liver biopsy
are being used to develop, commercialized, and are being used more and more in practices.
The current serum tests are a start and may have utility in identifying patients with minimal
fibrosis who do not require a liver biopsy. Because of the conditional relationship with biopsy,
the development of serum markers will always have obvious limitations. The use of noninva-
sive tools varies widely depending on practice setting and the individual physician’s manage-
ment style. However, as with many new diagnostic methodologies, such tests are being
adopted and marketed while the evidence of their general usefulness in various clinical set-
tings remains incomplete. For instance, there is no solid evidence that the currently available
tests for liver fibrosis have the precision necessary for tracing disease progression in real time
or patient’s response to therapy. Before such tests are accepted, their superiority to routine
laboratory studies should be demonstrated. Although invasive liver biopsy is still the gold
standard to assess the nature and severity of hepatic fibrosis, it has several recognized limita-
tions including sampling error and inter-observer variability in interpretation and staging.
Furthermore, the dynamic process of fibrosis resulting from progression and regression is
difficult to capture with biopsy alone. Therefore, alternative, simple, reliable, and noninvasive
direct and indirect serum markers able to predict the presence of significant fibrosis or cirrho-
sis in patients with chronic liver disease with considerable accuracy were needed. The
hepatology experts are actively researching noninvasive methods of fibrosis quantification.
This chapter reviewed the nature and limitations of the several noninvasive methods for the
assessment of the presence and severity of liver fibrosis in patients with chronic liver disease.
Author details
Ju-Seop Kang1* and Min-Ho Lee2
*Address all correspondence to: jskang@hanyang.ac.kr
1 Department of Pharmacology, College of Medicine, Hanyang University, Seoul, South Korea
2 Department of Internal Medicine, College of Medicine, Ministry of Food and Drug Safety,
Hanyang University, Seoul, South Korea
References
[1] Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The
natural history of nonalcoholic fatty liver disease: A population-based cohort study.
Gastroenterology. 2005;129:113–121
[2] Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and
cirrhosis. World Journal of Gastroenterology. 2014;20:16820–16830. DOI: 10.3748/wjg.
v20.i45.16820
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
57
[3] Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated
cirrhosis: Natural history and prognostic factors. Hepatology (Baltimore, Md).
1987;7:122–128
[4] D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of
survival in cirrhosis: A systematic review of 118 studies. Journal of Hepatology.
2006;44:217–231. DOI: 10.1016/j.jhep.2005.10.013
[5] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients
with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
Lancet (London, England). 1997;349:825–832
[6] Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Nonin-
vasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with
chronic hepatitis C. Gastroenterology. 2011;140:1970–1979, 9.e1-3. DOI: 10.1053/j.
gastro.2011.02.058
[7] Bravo AA, Sheth SG, Chopra S. Liver biopsy. The New England Journal of Medicine.
2001;344:495–500. DOI: 10.1056/nejm200102153440706
[8] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C.
The METAVIR Cooperative Study Group. Hepatology (Baltimore, Md). 1996;24:289–
293. DOI: 10.1002/hep.510240201
[9] Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading
and staging of chronic hepatitis. Journal of Hepatology. 1995;22:696–699
[10] Tsochatzis E, Bruno S, Isgro G, Hall A, Theocharidou E, Manousou P, et al. Collagen
proportionate area is superior to other histological methods for sub-classifying cirrhosis
and determining prognosis. Journal of Hepatology. 2014;60:948–954. DOI: 10.1016/j.
jhep.2013.12.023
[11] Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective
nationwide survey. For the Group of Epidemiology of the French Association for the
Study of the Liver (AFEF). Hepatology (Baltimore, Md). 2000;32:477–481. DOI: 10.1053/
jhep.2000.16602
[12] Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al. Complication
rate of percutaneous liver biopsies among persons with advanced chronic liver disease
in the HALT-C trial. Clinical Gastroenterology and Hepatology: The Official Clinical
Practice Journal of the American Gastroenterological Association. 2010;8:877–883. DOI:
10.1016/j.cgh.2010.03.025
[13] Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic
hepatitis C. Hepatology (Baltimore, Md). 2003;38:1449–1457. DOI: 10.1016/j.hep.2003.
09.022
[14] Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling
error and intraobserver variation in liver biopsy in patients with chronic HCV infection.
Liver Cirrhosis - Update and Current Challenges58
The American Journal of Gastroenterology. 2002;97:2614–2618. DOI: 10.1111/j.1572-
0241.2002.06038.x
[15] Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, et al. Prog-
nostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term
treatment against cirrhosis trial. Hepatology (Baltimore, Md). 2010;51:585–594. DOI:
10.1002/hep.23315
[16] European Association for the Study of the Liver Association Latinoamericana para el
Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evalua-
tion of liver disease severity and prognosis. Journal of Hepatology. 2015;63:237–264.
DOI: http://dx.doi.org/10.1016/j.jhep.2015.04.006
[17] Bedossa P, Carrat F. Liver biopsy: The best, not the gold standard. Journal of
Hepatology. 2009;50:1–3. DOI: 10.1016/j.jhep.2008.10.014
[18] Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients
with chronic liver disease. Therapeutic Advances in Gastroenterology. 2011;4:391–417.
DOI: 10.1177/1756283x11413002
[19] Castera L. Assessing liver fibrosis. Expert Review of Gastroenterology & Hepatology.
2008;2:541–552. DOI: 10.1586/17474124.2.4.541
[20] Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis
reversible? Liver International. 2014;34:85–90
[21] Grigorescu M. Noninvasive biochemical markers of liver fibrosis. Journal of Gastroin-
testinal and Liver Diseases: JGLD. 2006;15:149–159
[22] Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient
elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound
in Medicine & Biology. 2003;29:1705–1713
[23] de Ledinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis.
Expert Review of Medical Devices. 2010;7:811–823. DOI: 10.1586/erd.10.46
[24] Friedman SL. Liver fibrosis—From bench to bedside. Journal of Hepatology. 2003;38(
Suppl 1):S38–S53
[25] Bataller R, Brenner DA. Liver fibrosis. The Journal of Clinical Investigation.
2005;115:209–218. DOI: 10.1172/jci24282
[26] Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annual Review of
Pathology. 2011;6:425–456. DOI: 10.1146/annurev-pathol-011110-130246
[27] Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Comprehen-
sive Physiology. 2013;3:1473–1492. DOI: 10.1002/cphy.c120035
[28] Iredale JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and
repair in a solid organ. The Journal of Clinical Investigation. 2007;117:539–548. DOI:
10.1172/jci30542
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
59
[29] Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Assessment of fibrosis
and cirrhosis in liver biopsies: An update. Seminars in Liver Disease. 2011;31:82–90.
DOI: 10.1055/s-0031-1272836
[30] Suk KT, Kim DJ. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure
gradient measurement. World Journal of Hepatology. 2015;7:607–615. DOI: 10.4254/wjh.
v7.i3.607
[31] Falize L, Guillygomarc’h A, Perrin M, Laine F, Guyader D, Brissot P, et al. Reversibility
of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases. Hepatology
(Baltimore, Md). 2006;44:472–477. DOI: 10.1002/hep.21260
[32] Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic
stellate cells. Seminars in Liver Disease. 2001;21:311–335. DOI: 10.1055/s-2001-17550
[33] Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic
fibrogenesis. Seminars in Liver Disease. 2001;21:351–372. DOI: 10.1055/s-2001-17556
[34] Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing
cells. Journal of Hepatology. 1995;22:28–36
[35] Olaso E, Ikeda K, Eng FJ, Xu L, Wang LH, Lin HC, et al. DDR2 receptor promotes MMP-
2-mediated proliferation and invasion by hepatic stellate cells. The Journal of Clinical
Investigation. 2001;108:1369–1378. DOI: 10.1172/jci12373
[36] Bataller R, Brenner DA, editors. Hepatic stellate cells as a target for the treatment of liver
fibrosis. Seminars in Liver Disease. NY, USA: Thieme Medical Publishers, Inc.; 2001
[37] Iredale JP, editor. Hepatic stellate cell behavior during resolution of liver injury. Semi-
nars in Liver Disease. NY, USA: Thieme Medical Publishers, Inc.; 2001
[38] Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. Gastroenterology.
1963;44:239–242
[39] Gressner A, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest
stellate cells and TGF-β as major players and therapeutic targets. Journal of Cellular
and Molecular Medicine. 2006;10:76–99
[40] Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, et al.
Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a trans-
genic mouse model. Hepatology (Baltimore, Md). 2000;32:1248–1254. DOI: 10.1053/
jhep.2000.20521
[41] Ebrahimi H, Naderian M, Sohrabpour AA. New concepts on pathogenesis and diagno-
sis of liver fibrosis; A review article. Middle East Journal of Digestive Diseases.
2016;8:166
[42] Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. Expression of tissue inhib-
itor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology.
1996;110:821–831
Liver Cirrhosis - Update and Current Challenges60
[43] Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, et al. Dual expression of matrix
metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human
livers. Hepatology (Baltimore, Md). 1997;26:1521–1529. DOI: 10.1002/hep.510260620
[44] Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis.
American Journal of Physiology Gastrointestinal and Liver Physiology. 2000;279:G245–
G249
[45] Wells RG, Schwabe RF. Origin and function of myofibroblasts in the liver. Seminars in
Liver Disease. 2015;35:97–106. DOI: 10.1055/s-0035-1550061
[46] Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–
1669. DOI: 10.1053/j.gastro.2008.03.003
[47] Parola M, Marra F, Pinzani M. Myofibroblast-like cells and liver fibrogenesis: Emerging
concepts in a rapidly moving scenario. Molecular Aspects of Medicine. 2008;29:58–66.
DOI: 10.1016/j.mam.2007.09.002
[48] Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, et al. Origin of
myofibroblasts in the fibrotic liver in mice. Proceedings of the National Academy of
Sciences of the United States of America. 2014;111:E3297–E3305. DOI: 10.1073/
pnas.1400062111
[49] Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis.
Hepatology (Baltimore, Md). 2010;51:1438–1444. DOI: 10.1002/hep.23405
[50] Lemoinne S, Cadoret A, Rautou PE, El Mourabit H, Ratziu V, Corpechot C, et al. Portal
myofibroblasts promote vascular remodeling underlying cirrhosis formation through
the release of microparticles. Hepatology (Baltimore, Md). 2015;61:1041–1055. DOI:
10.1002/hep.27318
[51] Brenner DA. Molecular pathogenesis of liver fibrosis. Transactions of the American
Clinical and Climatological Association. 2009;120:361–368
[52] Carotti S, Morini S, Corradini SG, Burza MA, Molinaro A, Carpino G, et al. Glial
fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic
and posttransplant recurrent hepatitis C. Liver Transplantation: Official Publication of
the American Association for the Study of Liver Diseases and the International Liver
Transplantation Society. 2008;14:806–814. DOI: 10.1002/lt.21436
[53] Kalluri R, Zeisberg M. Fibroblasts in cancer. Nature Reviews Cancer. 2006;6:392–401.
DOI: 10.1038/nrc1877
[54] Moreira RK. Hepatic stellate cells and liver fibrosis. Archives of Pathology & Laboratory
Medicine. 2007;131:1728–1734. DOI: 10.1043/1543-2165(2007)131[1728:hscalf]2.0.co;2
[55] Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease.
Liver International: Official Journal of the International Association for the Study of the
Liver. 2006;26:1175–1186. DOI: 10.1111/j.1478-3231.2006.01342.x
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
61
[56] Bachem MG, Melchior R, Gressner AM. The role of thrombocytes in liver fibrogenesis:
Effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic
activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. Journal
of Clinical Chemistry and Clinical Biochemistry Zeitschrift fur Klinische Chemie und
Klinische Biochemie. 1989;27:555–565
[57] Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Review of
Gastroenterology & Hepatology. 2008;2:803–816. DOI: 10.1586/17474124.2.6.803
[58] Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Annals of Hepatology.
2009;8:283–291
[59] Elpek GO. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An
update. World Journal of Gastroenterology. 2014;20:7260–7276. DOI: 10.3748/wjg.v20.
i23.7260
[60] Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/
myofibroblast subpopulations in fibrotic human and rat livers. Journal of Hepatology.
2002;36:200–209
[61] Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver
disease. Journal of Hepatology. 2009;50:604–620. DOI: 10.1016/j.jhep.2008.12.011
[62] Lee RG. Diagnostic Liver Pathology. Mosby Inc.; 1994.
[63] Germani G, Burroughs AK, Dhillon AP. The relationship between liver disease stage and
liver fibrosis: A tangled web. Histopathology. 2010;57:773–784. DOI: 10.1111/j.1365-
2559.2010.03609.x
[64] Stanley AJ, Haydon GH, Piris J, Jarvis LM, Hayes PC. Assessment of liver histology in
patients with hepatitis C and normal transaminase levels. European Journal of Gastro-
enterology & Hepatology. 1996;8:869–872
[65] Diehl AM. Alcoholic liver disease. The Medical Clinics of North America. 1989;73:815–830
[66] Locke GR, 3rd, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of
histological progression in primary biliary cirrhosis. Hepatology (Baltimore, Md).
1996;23:52–56. DOI: 10.1002/hep.510230108
[67] Bach N, Thung SN, Schaffner F. The histologic effects of low-dose methotrexate therapy
for primary biliary cirrhosis. Archives of Pathology & Laboratory Medicine.
1998;122:342
[68] Hultcrantz R, Gabrielsson N. Patients with persistent elevation of aminotransferases:
Investigation with ultrasonography, radionuclide imaging and liver biopsy. Journal of
Internal Medicine. 1993;233:7–12
[69] Brown KE, Janney C, Brunt EM. Liver biopsy: Indications, technique, complications, and
interpretation. In: Bacon BR, Di Bisceglie AM Churchill Livingstone, editors. Liver
Disease: Diagnosis and Management. New York, NY; 2000
Liver Cirrhosis - Update and Current Challenges62
[70] Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al. Sources of
variability in histological scoring of chronic viral hepatitis. Hepatology (Baltimore, Md).
2005;41:257–264. DOI: 10.1002/hep.20535
[71] Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histolog-
ical evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease.
Journal of Hepatology. 2003;39:239–244
[72] Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the
histopathological assessment of liver fibrosis. Gut. 2006;55:569–578. DOI: 10.1136/
gut.2005.084475
[73] Colombo M, Del Ninno E, de Franchis R, De Fazio C, Festorazzi S, Ronchi G, et al.
Ultrasound-assisted percutaneous liver biopsy: Superiority of the Tru-Cut over the
Menghini needle for diagnosis of cirrhosis. Gastroenterology. 1988;95:487–489
[74] EASL International Consensus Conference on Hepatitis C. Paris, 26–27 February 1999.
Consensus statement. Journal of Hepatology. 1999;31(Supp l 1):3–8
[75] Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation
and application of a numerical scoring system for assessing histological activity in
asymptomatic chronic active hepatitis. Hepatology (Baltimore, Md). 1981;1:431–435
[76] Group TFMC. Intraobserver and interobserver variations in liver biopsy interpretation
in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.
Hepatology (Baltimore, Md). 1994;20:15–20
[77] Hubscher SG. Histological grading and staging in chronic hepatitis: Clinical applica-
tions and problems. Journal of Hepatology. 1998;29:1015–1022
[78] Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. Journal of
Hepatology. 1991;13:372–374
[79] Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. The
American Journal of Surgical Pathology. 1995;19:1409–1417
[80] Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al. Lack of
progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with
transfusion-dependent beta-thalassemia. Blood. 2002;100:1566–1569. DOI: 10.1182/
blood-2002-01-0306
[81] Fiel MI. Histologic scoring systems for chronic liver disease. UpToDate com. 2016:1–70.
Available from: https://www.uptodate.com/contents/histologic-scoring-systems-for-chronic-
liver-disease. [Accessed: 23 January, 2017]
[82] The Merck Manual Wolters Kluwer; 19th ed. Elsevier; 2011
[83] Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY, Shaffer EA. Testing for hepatic and biliary
disorders. Noninvasive models for assessment of liver fibrosis in patients with chronic
hepatitis B virus infection. World Journal of Gastroenterology. 2016;22:6663–6672. DOI:
10.3748/wjg.v22.i29.6663
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
63
[84] Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: “Something old,
something new…”. Annals of Gastroenterology: Quarterly Publication of the Hellenic
Society of Gastroenterology. 2016;29:445–453. DOI: 10.20524/aog.2016.0046
[85] Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical
practice guidelines on the management of hepatitis B: A 2015 update. Hepatology
International. 2016;10:1–98. DOI: 10.1007/s12072-015-9675-4
[86] EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver
disease severity and prognosis. Journal of Hepatology. 2015;63:237–264. DOI: 10.1016/j.
jhep.2015.04.006
[87] Tonami N, Nakajima K, Hisada K, Tanaka N, Kobayashi K. A noninvasive method for
evaluating portal circulation by administration of Ti-201 per rectum. Journal of Nuclear
Medicine: Official Publication, Society of Nuclear Medicine. 1982;23:965–972
[88] Bradley-Moore PR, Lebowitz E, Greene MW, Atkins HL, Ansari AN. Thallium-201 for
medical use. II: Biologic behavior. Journal of Nuclear Medicine: Official Publication,
Society of Nuclear Medicine. 1975;16:156–160
[89] Urbain D, Muls V, Makhoul E, Ham HR. Prognostic value of thallium-201 per rectum
scintigraphy in alcoholic cirrhosis. Journal of Nuclear Medicine: Official Publication,
Society of Nuclear Medicine. 1994;35:832–834
[90] Lee MH, Tae HJ, Jun DW, Ryu SE, Choi YY, Kwak MJ, et al. 201Tl heart-liver radioactiv-
ity uptake ratio and prediction of decompensation in patients with cirrhosis. Clinical
Nuclear Medicine. 2013;38:169–174. DOI: 10.1097/RLU.0b013e31827087e3
[91] Park MS, Lee MH, Park YS, Kim SH, Kwak MJ, Kang JS. Abnormal gas diffusing
capacity and portosystemic shunt in patients with chronic liver disease. Gastroenterol-
ogy Research. 2012;5:182–189. DOI: 10.4021/gr475e
[92] Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, et al. The impact of liver
disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive
fibrosis biomarkers: An international study of 2411 cases. Alimentary Pharmacology &
Therapeutics. 2011;34:1202–1216. DOI: 10.1111/j.1365-2036.2011.04861.x
[93] Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers
for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clinical
Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American
Gastroenterological Association. 2005;3:167–174
[94] Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N, et al. Diagnostic
and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic
liver disease. Hepatology (Baltimore, Md). 2009;49:97–105. DOI: 10.1002/hep.22576
[95] Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al.
Complex non-invasive fibrosis models are more accurate than simple models in non-
Liver Cirrhosis - Update and Current Challenges64
alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2011;26:1536-–
1543. DOI: 10.1111/j.1440-1746.2011.06774.x
[96] Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers asso-
ciated with liver fibrosis in non-alcoholic fatty liver disease. Gut. 2006;55:1650–1660.
DOI: 10.1136/gut.2006.091454
[97] Lee KS, Hwang SH, Hahm JS, Rhee JC, Kee CS, Park KN, et al. Clinical significance of
ICG—Rmax and thallium—201 test per rectum in chronic liver disease. Korean Journal
of Medicine (구대한내과학회지). 1994;46:19–26
[98] Park GT, Jeon DW, Yoo YJ, Choi CS, Jung JW, Kim JB, et al. Correlation analysis and
clinical significance of various noninvasive examinations to determine the progression
of chronic liver disease. The Korean Journal of Gastroenterology. 1999;33:799–807
[99] Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease
progression in chronic liver disease. Best Practice & Research Clinical Gastroenterology.
2011;25:291–303. DOI: 10.1016/j.bpg.2011.02.003
[100] Song SW. Using the receiver operating characteristic (ROC) curve to measure sensitivity
and specificity. Korean Journal of Family Medicine. 2009;30:841–842
[101] Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology
markers. Journal of Hepatology. 2009;50:36–41. DOI: 10.1016/j.jhep.2008.07.039
[102] Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Perfor-
mance of transient elastography for the staging of liver fibrosis: A meta-analysis. Gas-
troenterology. 2008;134:960–974. DOI: 10.1053/j.gastro.2008.01.034
[103] Poynard T, Halfon P, Castera L, Charlotte F, Le Bail B, Munteanu M, et al. Variability of
the area under the receiver operating characteristic curves in the diagnostic evaluation
of liver fibrosis markers: Impact of biopsy length and fragmentation. Alimentary Phar-
macology & Therapeutics. 2007;25:733–739. DOI: 10.1111/j.1365-2036.2007.03252.x
[104] Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. Stan-
dardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based
on prevalences of fibrosis stages. Clinical Chemistry. 2007;53:1615–1622. DOI: 10.1373/
clinchem.2007.085795
[105] Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F. How to measure the
diagnostic accuracy of noninvasive liver fibrosis indices: The area under the ROC curve
revisited. Clinical Chemistry. 2008;54:1372–1378. DOI: 10.1373/clinchem.2007.097923
[106] Obuchowski NA. An ROC-type measure of diagnostic accuracy when the gold standard
is continuous-scale. Statistics in Medicine. 2006;25:481–493. DOI: 10.1002/sim.2228
[107] Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis.
Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroen-
terology. 2012;25:218–231
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
65
[108] Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. The American
Journal of Gastroenterology. 2004;99:1160–1174. DOI: 10.1111/j.1572-0241.2004.30110.x
[109] Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective
comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assess-
ment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350
[110] McGary CT, Raja RH, Weigel PH. Endocytosis of hyaluronic acid by rat liver endothelial
cells. Evidence for receptor recycling. The Biochemical Journal. 1989;257:875–884
[111] Gibson PR, Fraser JR, Brown TJ, Finch CF, Jones PA, Colman JC, et al. Hemodynamic
and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology
(Baltimore, Md). 1992;15:1054–1059
[112] McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, et al. Measure-
ment of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to
liver histology. Consensus Interferon Study Group. Journal of Gastroenterology and
Hepatology. 2000;15:945–951
[113] Pares A, Deulofeu R, Gimenez A, Caballeria L, Bruguera M, Caballeria J, et al. Serum
hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a
marker of fibrosis. Hepatology (Baltimore, Md). 1996;24:1399–1403
[114] Curry M, Nezam H. Noninvasive assessment of hepatic fibrosis: Overview of serologic
and radiographic tests. UpToDate com. 2016. Available from: https://www.uptodate.
com/contents/noninvasive-assessment-of-hepatic-fibrosis-overview-of-serologic-and-
radiographic-tests. [Accessed: 23 January, 2017]
[115] Ramadori G, Zohrens G, Manns M, Rieder H, Dienes HP, Hess G, et al. Serum
hyaluronate and type III procollagen aminoterminal propeptide concentration in
chronic liver disease. Relationship to cirrhosis and disease activity. European Journal of
Clinical Investigation. 1991;21:323–330
[116] Niemela O, Risteli J, Blake JE, Risteli L, Compton KV, Orrego H. Markers of fibrogenesis
and basement membrane formation in alcoholic liver disease. Relation to severity, pres-
ence of hepatitis, and alcohol intake. Gastroenterology. 1990;98:1612–1619
[117] Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. Histopatho-
logical evaluation of liver fibrosis: Quantitative image analysis vs semi-quantitative
scores. Comparison with serum markers. Journal of Hepatology. 1998;28:439–446
[118] Leroy V, De Traversay C, Barnoud R, Hartmann JD, Baud M, Ouzan D, et al. Changes in
histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-
responders to interferon alpha. Journal of Hepatology. 2001;35:120–126
[119] Giustina G, Fattovich G, De Paoli M, Guido M, Favarato S, Rugge M, et al. Serum
procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and
response to interferon-alpha therapy. International Journal of Clinical & Laboratory
Research. 1996;26:33–36
Liver Cirrhosis - Update and Current Challenges66
[120] Yamada M, Fukuda Y, Nakano I, Katano Y, Takamatsu J, Hayakawa T. Serum
hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associ-
ated chronic liver disease. Acta Haematologica. 1998;99:212–216. DOI: 40841
[121] Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis:
markers of progression with high prognostic value. Journal of Hepatology. 1996;25:
684–688
[122] Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels
of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.
Journal of Hepatology. 2003;39:179–186
[123] Anderson FH, Zeng L, Rock NR, Yoshida EM. An assessment of the clinical utility of
serum ALTand AST in chronic hepatitis C. Hepatology Research: The Official Journal of
the Japan Society of Hepatology. 2000;18:63–71
[124] Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision
aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. The Amer-
ican Journal of Gastroenterology. 2000;95:2328–2332. DOI: 10.1111/j.1572-0241.2000.
02322.x
[125] Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients
with chronic hepatitis C virus infection. The American Journal of Gastroenterology.
1998;93:44–48. DOI: 10.1111/j.1572-0241.1998.044_c.x
[126] Croquet V, Vuillemin E, Ternisien C, Pilette C, Oberti F, Gallois Y, et al. Prothrombin
index is an indirect marker of severe liver fibrosis. European Journal of Gastroenterol-
ogy & Hepatology. 2002;14:1133–1141
[127] Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, et al. A simple biological
index for detection of alcoholic liver disease in drinkers. Gastroenterology. 1991;100:
1397–1402
[128] Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and
hepatic fibrosis. Diagnostic interest. Digestive Diseases and Sciences. 1994;39:2426–
2432
[129] Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, et al. Comparison
of serum procollagen III peptide concentrations and PGA index for assessment of
hepatic fibrosis. Lancet (London, England). 1993;342:895–898
[130] Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, et al. Noninvasive
markers for staging fibrosis in chronic delta hepatitis. Alimentary Pharmacology &
Therapeutics. 2017;45:127–138. DOI: 10.1111/apt.13834
[131] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A
simple noninvasive index can predict both significant fibrosis and cirrhosis in patients
with chronic hepatitis C. Hepatology (Baltimore, Md). 2003;38:518–526. DOI: 10.1053/
jhep.2003.50346
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
67
[132] Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-
Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver
fibrosis. Annals of Hepatology. 2008;7:350–357
[133] Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: Alanine
aminotransferase ratio in chronic hepatitis C infection: Is it a useful predictor of cirrho-
sis? Journal of Gastroenterology and Hepatology. 2000;15:386–390
[134] Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in
patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md). 1999;30:1356–
1362. DOI: 10.1002/hep.510300604
[135] Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase
levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus
infection. The American Journal of Gastroenterology. 2001;96:3142–3146. DOI: 10.1111/
j.1572-0241.2001.05268.x
[136] Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, et al. Noninvasive
diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology. 1997;113:1609–1616
[137] Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical
markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study.
Lancet (London, England). 2001;357:1069–1075. DOI: 10.1016/s0140-6736(00)04258-6
[138] Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al.
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest,
HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Compara-
tive Hepatology. 2004;3:8. DOI: 10.1186/1476-5926-3-8
[139] Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the
FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.
Clinical Chemistry. 2003;49:450–454
[140] Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-inva-
sive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World
Journal of Gastroenterology. 2007;13:525–531
[141] Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, et al. Longitudinal
assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine ther-
apy in patients with chronic hepatitis B infection. The American Journal of Gastroenter-
ology. 2005;100:1970–1980. DOI: 10.1111/j.1572-0241.2005.41957.x
[142] Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum
biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus
co-infected patients. AIDS (London, England). 2003;17:721–725. DOI: 10.1097/01.
aids.0000050827.06065.16
[143] Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diag-
nostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver
Liver Cirrhosis - Update and Current Challenges68
fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology.
2006;6:6. DOI: 10.1186/1471-230x-6-6
[144] Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, et al. Diagnos-
tic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic
hepatitis C virus. Transplantation. 2005;80:1550–1555
[145] Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, et al. Assessment
of liver fibrosis: Noninvasive means. Saudi Journal of Gastroenterology: Official Journal
of the Saudi Gastroenterology Association. 2008;14:163–173. DOI: 10.4103/1319-
3767.43273
[146] Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective
comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic
hepatitis C. Journal of Hepatology. 2007;46:775–782. DOI: 10.1016/j.jhep.2006.12.013
[147] Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: An
accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clinical
Chemistry. 2005;51:1867–1873. DOI: 10.1373/clinchem.2005.048389
[148] Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel
of non-invasive serum markers to differentiate mild from moderate-to-advanced liver
fibrosis in chronic hepatitis C patients. Journal of Hepatology. 2004;41:935–942. DOI:
10.1016/j.jhep.2004.08.008
[149] Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel
panel of blood markers to assess the degree of liver fibrosis. Hepatology (Baltimore,
Md). 2005;42:1373–1381. DOI: 10.1002/hep.20935
[150] Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, et al. Modeling
hepatic fibrosis in African American and Caucasian American patients with chronic
hepatitis C virus infection. Hepatology (Baltimore, Md). 2006;44:925–935. DOI: 10.1002/
hep.21335
[151] Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R.
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum pro-
tein glycomics. Nature Medicine. 2004;10:429–434
[152] Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of
fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index.
Hepatology (Baltimore, Md). 2004;39:1239–1247. DOI: 10.1002/hep.20207
[153] Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients
can be excluded using an index of standard biochemical serum markers. Scandinavian
Journal of Gastroenterology. 2005;40:867–872. DOI: 10.1080/00365520510015674
[154] Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identi-
fication of chronic hepatitis C patients without hepatic fibrosis by a simple predictive
model. Hepatology (Baltimore, Md). 2002;36:986–992. DOI: 10.1053/jhep.2002.36128
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
69
[155] Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum
markers detect the presence of liver fibrosis: A cohort study. Gastroenterology.
2004;127:1704–1713
[156] Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in
overweight patients. Gastroenterology. 2000;118:1117–1123
[157] Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and
validation of a simple NAFLD clinical scoring system for identifying patients without
advanced disease. Gut. 2008;57:1441–1447. DOI: 10.1136/gut.2007.146019
[158] Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD
fibrosis score: A noninvasive system that identifies liver fibrosis in patients with
NAFLD. Hepatology (Baltimore, Md). 2007;45:846–854. DOI: 10.1002/hep.21496
[159] Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of
noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clinical
Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American
Gastroenterological Association. 2009;7:1104–1112. DOI: 10.1016/j.cgh.2009.05.033
[160] Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: Non-invasive
investigation and risk stratification. Journal of Clinical Pathology. 2013;66:1033–1045.
DOI: 10.1136/jclinpath-2013-201620
[161] Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combi-
nation algorithms of non-invasive markers to diagnose significant fibrosis in chronic
hepatitis C. Journal of Hepatology. 2006;44:686–693. DOI: 10.1016/j.jhep.2006.01.007
[162] Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, et al. Validation
and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C
patients: Proposal for a pragmatic approach classification without liver biopsies. Journal
of Viral Hepatitis. 2006;13:659–670. DOI: 10.1111/j.1365-2893.2006.00736.x
[163] Thabut D, Simon M, Myers RP, Messous D, Thibault V, Imbert-Bismut F, et al. Noninva-
sive prediction of fibrosis in patients with chronic hepatitis C. Hepatology (Baltimore,
Md). 2003;37:1220–1221; author reply 1. DOI: 10.1053/jhep.2003.50109
[164] Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, et al. The
role of laparoscopy in the diagnosis of cirrhosis. Gastrointestinal Endoscopy. 1996;43:
568–571
[165] Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role
of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology
(Baltimore, Md). 2002;36
[166] Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and
validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.
Hepatology (Baltimore, Md). 2005;41:1376–1382. DOI: 10.1002/hep.20717
Liver Cirrhosis - Update and Current Challenges70
[167] Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. The
predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
Hepatology (Baltimore, Md). 2004;39:862–863; author reply 3. DOI: 10.1002/hep.20099
[168] Fraser JR, Gibson PR. Mechanisms by which food intake elevates circulating levels of
hyaluronan in humans. Journal of Internal Medicine. 2005;258:460–466. DOI: 10.1111/
j.1365-2796.2005.01564.x
[169] Yamada N, Uzuki M, Rikimaru A, Sakurai M, Sawai T. Increased levels of circulating
hyaluronate in the sera of patients with rheumatoid arthritis with special reference to
joint destruction. Ryumachi [Rheumatism]. 1994;34:752–760
[170] Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors
associated with serum alanine transaminase activity in healthy subjects: Consequences
for the definition of normal values, for selection of blood donors, and for patients with
chronic hepatitis C. MULTIVIRC Group. Hepatology (Baltimore, Md). 1998;27:1213–
1219. DOI: 10.1002/hep.510270505
[171] Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al.
Prospective analysis of discordant results between biochemical markers and biopsy in
patients with chronic hepatitis C. Clinical Chemistry. 2004;50:1344–1355. DOI: 10.1373/
clinchem.2004.032227
[172] Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the
need for liver biopsy. World Journal of Gastroenterology. 2006;12:3682–3694
[173] Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: A
validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
Hepatology (Baltimore, Md). 2009;49:1821–1827. DOI: 10.1002/hep.22859
[174] Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective
comparison of two algorithms combining non-invasive methods for staging liver fibro-
sis in chronic hepatitis C. Journal of Hepatology. 2010;52:191–198. DOI: 10.1016/j.
jhep.2009.11.008
[175] Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK.
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-
analysis of diagnostic accuracy. Journal of Hepatology. 2011;54:650–659. DOI: 10.1016/j.
jhep.2010.07.033
[176] Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based
transient elastography for the detection of hepatic fibrosis: Systematic review and
meta-analysis. Clinical Gastroenterology and Hepatology: The Official Clinical Practice
Journal of the American Gastroenterological Association. 2007;5:1214–1220. DOI:
10.1016/j.cgh.2007.07.020
[177] Chin JL, Farrelly A, Chan G, Norris S, McCormick PA. Liver stiffness changes during
meal times. Hepatology (Baltimore, Md). 2014;60:432. DOI: 10.1002/hep.26922
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
71
[178] Tsochatzis EA, Burroughs AK. Liver stiffness measurements increase after meal inges-
tion—An important step towards standardization. Annals of Hepatology. 2013;12:839–
840
[179] Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, et al. Transient
elastography: A new surrogate marker of liver fibrosis influenced by major changes of
transaminases. Journal of Viral Hepatitis. 2007;14:360–369. DOI: 10.1111/j.1365-
2893.2006.00811.x
[180] Gomez-Dominguez E, Mendoza J, Rubio S, Moreno-Monteagudo JA, Garcia-Buey L,
Moreno-Otero R. Transient elastography: A valid alternative to biopsy in patients with
chronic liver disease. Alimentary Pharmacology & Therapeutics. 2006;24:513–518. DOI:
10.1111/j.1365-2036.2006.02999.x
[181] Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive
assessment of liver fibrosis by measurement of stiffness in patients with chronic hepati-
tis C. Hepatology (Baltimore, Md). 2005;41:48–54. DOI: 10.1002/hep.20506
[182] Takeda T, Yasuda T, Nakayama Y, Nakaya M, Kimura M, Yamashita M, et al. Usefulness
of noninvasive transient elastography for assessment of liver fibrosis stage in chronic
hepatitis C. World Journal of Gastroenterology. 2006;12:7768–7773
[183] Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al.
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with
chronic liver diseases. Hepatology (Baltimore, Md). 2006;44:1511–1517. DOI: 10.1002/
hep.21420
[184] Vergara S, Macias J, Rivero A, Gutierrez-Valencia A, Gonzalez-Serrano M, Merino D,
et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV
and hepatitis C virus coinfection. Clinical Infectious Diseases: An Official Publication of
the Infectious Diseases Society of America. 2007;45:969–974. DOI: 10.1086/521857
[185] Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, et al. Real-time
elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis.
American Journal of Roentgenology. 2007;188:758–764. DOI: 10.2214/ajr.06.0322
[186] Arena U, Vizzutti F, Abraldes JG, Corti G, Stasi C, Moscarella S, et al. Reliability of
transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut.
2008;57:1288–1293. DOI: 10.1136/gut.2008.149708
[187] Wong GL, Wong VW, Choi PC, Chan AW, Chum RH, Chan HK, et al. Assessment of
fibrosis by transient elastography compared with liver biopsy and morphometry in
chronic liver diseases. Clinical Gastroenterology and Hepatology: The Official Clinical
Practice Journal of the American Gastroenterological Association. 2008;6:1027–1035.
DOI: 10.1016/j.cgh.2008.02.038
[188] Chang PE, Lui HF, Chau YP, Lim KH, Yap WM, Tan CK, et al. Prospective evaluation of
transient elastography for the diagnosis of hepatic fibrosis in Asians: Comparison with
Liver Cirrhosis - Update and Current Challenges72
liver biopsy and aspartate transaminase platelet ratio index. Alimentary Pharmacology
& Therapeutics. 2008;28:51–61. DOI: 10.1111/j.1365-2036.2008.03711.x
[189] Sharma P, Dhawan S, Bansal R, Tyagi P, Bansal N, Singla V, et al. Usefulness of transient
elastography by FibroScan for the evaluation of liver fibrosis. Indian journal of Gastro-
enterology: Official Journal of the Indian Society of Gastroenterology. 2014;33:445-51.
DOI: 10.1007/s12664-014-0491-x
[190] Lupsor M, Badea R, Stefanescu H, Grigorescu M, Sparchez Z, Serban A, et al. Analysis of
histopathological changes that influence liver stiffness in chronic hepatitis C. Results from
a cohort of 324 patients. Journal of Gastrointestinal and Liver Diseases. 2008;17:155–163
[191] Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C.
Gastroenterology. 2012;142:1293–1302. e4
[192] Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Ledinghen V, et al. Non-
invasive assessment of liver fibrosis by stiffness measurement in patients with chronic
hepatitis B. Liver International: Official Journal of the International Association for the
Study of the Liver. 2009;29:242–247. DOI: 10.1111/j.1478-3231.2008.01802.x
[193] Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, et al. Diagnostic
accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral
hepatitis: A multicenter prospective study (the FIBROSTIC study). Journal of
Hepatology. 2010;53:1013–1021. DOI: 10.1016/j.jhep.2010.05.035
[194] Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, et al. Magnetic reso-
nance elastography for the noninvasive staging of liver fibrosis. Gastroenterology.
2008;135:32–40. DOI: 10.1053/j.gastro.2008.03.076
[195] Rouviere O, Yin M, Dresner MA, Rossman PJ, Burgart LJ, Fidler JL, et al. MR
elastography of the liver: Preliminary results. Radiology. 2006;240:440–448. DOI:
10.1148/radiol.2402050606
[196] Huwart L, Peeters F, Sinkus R, Annet L, Salameh N, ter Beek LC, et al. Liver fibrosis:
Non-invasive assessment with MR elastography. NMR in Biomedicine. 2006;19:173–179.
DOI: 10.1002/nbm.1030
[197] Huwart L, Sempoux C, Salameh N, Jamart J, Annet L, Sinkus R, et al. Liver fibrosis:
noninvasive assessment with MR elastography versus aspartate aminotransferase-to-
platelet ratio index. Radiology. 2007;245:458–66. DOI: 10.1148/radiol.2452061673
[198] Shi Y, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, et al. MR elastography for the
assessment of hepatic fibrosis in patients with chronic hepatitis B infection: Does histo-
logic necroinflammation influence the measurement of hepatic stiffness? Radiology.
2014;273:88–98. DOI: 10.1148/radiol.14132592
[199] Wu W-P, Chou C-T, Chen R-C, Lee C-W, Lee K-W, Wu H-K. Non-invasive evaluation of
hepatic fibrosis: The diagnostic performance of magnetic resonance elastography in
patients with viral hepatitis B or C. PLoS One. 2015;10:e0140068
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
73
[200] Yin M, Talwalkar JA, Glaser KJ, Venkatesh SK, Chen J, Manduca A, et al. Dynamic
postprandial hepatic stiffness augmentation assessed with MR elastography in patients
with chronic liver disease. American Journal of Roentgenology. 2011;197:64–70. DOI:
10.2214/ajr.10.5989
[201] Lupsor M, Badea R, Stefanescu H, Sparchez Z, Branda H, Serban A, et al. Performance of
a new elastographic method (ARFI technology) compared to unidimensional transient
elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results.
Journal of Gastrointestinal and Liver Diseases: JGLD. 2009;18:303–310
[202] Zhai L, Palmeri ML, Bouchard RR, Nightingale RW, Nightingale KR. An integrated
indenter-ARFI imaging system for tissue stiffness quantification. Ultrasonic Imaging.
2008;30:95–111
[203] Wong G. Transient elastography: Kill two birds with one stone. World Journal of
Hepatology. 2013;5:264–274
[204] Giuseppetti GM, Martegani A, Di Cioccio B, Baldassarre S. Elastosonography in the
diagnosis of the nodular breast lesions: Preliminary report. La Radiologia Medica.
2005;110:69–76
[205] Konig K, Scheipers U, Pesavento A, Lorenz A, Ermert H, Senge T. Initial experiences
with real-time elastography guided biopsies of the prostate. The Journal of Urology.
2005;174:115–117. DOI: 10.1097/01.ju.0000162043.72294.4a
[206] Leung VY, Shen J, Wong VW, Abrigo J, Wong GL, Chim AM, et al. Quantitative
elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: Com-
parison of shear-wave elastography and transient elastography with liver biopsy corre-
lation. Radiology. 2013;269:910–918. DOI: 10.1148/radiol.13130128
[207] Poynard T, Munteanu M, Luckina E, Perazzo H, Ngo Y, Royer L, et al. Liver fibrosis
evaluation using real-time shear wave elastography: Applicability and diagnostic
performance using methods without a gold standard. Journal of Hepatology.
2013;58:928–935. DOI: 10.1016/j.jhep.2012.12.021
[208] Elkrief L, Rautou P-E, Ronot M, Lambert S, Dioguardi Burgio M, Francoz C, et al. Prospec-
tive comparison of spleen and liver stiffness by using shear-wave and transient
elastography for detection of portal hypertension in cirrhosis. Radiology. 2014;275:589–598
[209] Cassinotto C, Lapuyade B, Mouries A, Hiriart JB, Vergniol J, Gaye D, et al. Non-invasive
assessment of liver fibrosis with impulse elastography: Comparison of Supersonic Shear
Imaging with ARFI and FibroScan(R). Journal of Hepatology. 2014;61:550–557. DOI:
10.1016/j.jhep.2014.04.044
[210] Ferral H, Male R, Cardiel M, Munoz L, Quiroz y Ferrari F. Cirrhosis: Diagnosis by liver
surface analysis with high-frequency ultrasound. Gastrointestinal Radiology. 1992;17:
74–78. DOI: 10.1007/bf01888512
Liver Cirrhosis - Update and Current Challenges74
[211] Simonovsky V. The diagnosis of cirrhosis by high resolution ultrasound of the liver
surface. The British Journal of Radiology. 1999;72:29–34. DOI: 10.1259/bjr.72.853.10341686
[212] Yamada H, Ebara M, Yamaguchi T, Okabe S, Fukuda H, Yoshikawa M, et al. A pilot
approach for quantitative assessment of liver fibrosis using ultrasound: Preliminary
results in 79 cases. Journal of Hepatology. 2006;44:68–75. DOI: 10.1016/j.jhep.2005.08.009
[213] Quaia E. Microbubble ultrasound contrast agents: An update. European Radiology.
2007;17:1995–2008. DOI: 10.1007/s00330-007-0623-0
[214] Abbattista T, Ridolfi F, Ciabattoni E, Marini F, Bendia E, Brunelli E, et al. Diagnosis of
liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonography. La Radio-
logia Medica. 2008;113:860–874. DOI: 10.1007/s11547-008-0292-3
[215] Vyas K, Gala B, Sawant P, Das HS, Kulhalli PM, Mahajan SS. Assessment of portal
hemodynamics by ultrasound color Doppler and laser Doppler velocimetry in liver
cirrhosis. Indian Journal of Gastroenterology: Official Journal of the Indian Society of
Gastroenterology. 2002;21:176–178
[216] Weickert U, Buttmann A, Jakobs R, Schilling D, Eickhoff A, Riemann JF. Diagnosis of
liver cirrhosis: A comparison of modified ultrasound and laparoscopy in 100 consecu-
tive patients. Journal of Clinical Gastroenterology. 2005;39:529–532
[217] D’Arienzo A, Celentano L, Scuotto A, Di Siervi P, Lombardi V, Squame G, et al. Thal-
lium-201 per rectum for the diagnosis of cirrhosis in patients with asymptomatic chronic
hepatitis. Hepatology (Baltimore, Md). 1988;8:785–787
[218] Kim J-M, Lee M-H, Yun Y-S, Bae J-H, Moon W, Jun D-W, et al. Predictive factors of
development and progression of esophageal varices in patients with liver cirrhosis.
Korean Journal of Medicine. 2006;70:378–385
Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with…
http://dx.doi.org/10.5772/intechopen.68317
75

